

# Drug Transport across the Blood–Brain Barrier

Journal of Cerebral Blood Flow and Metabolism  
32, 1959-1972

DOI: [10.1038/jcbfm.2012.126](https://doi.org/10.1038/jcbfm.2012.126)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery. <i>Journal of Investigative Medicine</i> , 2012, 60, 1131-1140.	0.7	34
2	Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development. , 2013, , 3-33.		10
3	Drug Delivery across the Bloodâ€“Brain Barrier. <i>Molecular Pharmaceutics</i> , 2013, 10, 1471-1472.	2.3	40
4	Analysing molecular polar surface descriptors to predict blood-brain barrier permeation. <i>International Journal of Computational Biology and Drug Design</i> , 2013, 6, 146.	0.3	65
5	Bispecific antibodies for delivery into the brain. <i>Current Opinion in Chemical Biology</i> , 2013, 17, 393-399.	2.8	71
6	Fundamentals of Pharmaceutical Nanoscience. , 2013, , .		16
7	Noninvasive and Targeted Drug Delivery to the Brain Using Focused Ultrasound. <i>ACS Chemical Neuroscience</i> , 2013, 4, 519-526.	1.7	106
8	The endothelial cell: An â€œearly responderâ€“in the development of insulin resistance. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2013, 14, 21-27.	2.6	68
9	Combination stroke therapy in the mouse with bloodâ€“brain barrier penetrating IgGâ€“GDNF and IgGâ€“TNF decoy receptor fusion proteins. <i>Brain Research</i> , 2013, 1507, 91-96.	1.1	28
10	Current options for drug delivery to the spinal cord. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 385-396.	2.4	61
12	Camelid single-domain antibody-fragment engineering for (pre)clinical <i>in vivo</i> molecular imaging applications: adjusting the bullet to its target. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1149-1160.	1.4	105
13	Accessing the Brain: The Nose may Know the Way. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 793-794.	2.4	31
14	Nanoparticles for Brain Drug Delivery. , 2013, 2013, 1-18.		352
15	Hemostasis and Alterations of the Central Nervous System. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 856-875.	1.5	25
16	Bioluminescent imaging of drug efflux at the bloodâ€“brain barrier mediated by the transporter ABCG2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20801-20806.	3.3	40
18	Design of brain imaging agents for positron emission tomography: do large bioconjugates provide an opportunity for <i>in vivo</i> brain imaging?. <i>Future Medicinal Chemistry</i> , 2013, 5, 1621-1634.	1.1	9
19	Exposure to lipophilic chemicals as a cause of neurological impairments, neurodevelopmental disorders and neurodegenerative diseases. <i>Interdisciplinary Toxicology</i> , 2013, 6, 103-110.	1.0	57
20	Which drug or drug delivery system can change clinical practice for brain tumor therapy?. <i>Neuro-Oncology</i> , 2013, 15, 656-669.	0.6	35

#	ARTICLE	IF	CITATIONS
21	More Than Hypomyelination in Pol-III Disorder. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 67-75.	0.9	27
22	Bioavailability of Endomorphins and the Blood-brain Barrier- A Review. <i>Medicinal Chemistry</i> , 2013, 10, 2-17.	0.7	15
23	Intranasal Fluorescent Nanocrystals for Longitudinal In Vivo Evaluation of Cerebral Microlesions. <i>Pharmaceutical Nanotechnology</i> , 2013, 1, 93-104.	0.6	14
24	Engineered nanomaterial uptake and tissue distribution: from cell to organism. <i>International Journal of Nanomedicine</i> , 2013, 8, 3255.	3.3	136
25	Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIV-associated encephalopathy. <i>Frontiers in Pharmacology</i> , 2013, 4, 140.	1.6	76
26	Transferrin Receptor Mediated Brain Uptake During Ischemia and Reperfusion. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 541.	0.9	7
27	Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 335.	1.8	37
28	Nanobodies as modulators of inflammation: potential applications for acute brain injury. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 344.	1.8	37
29	Stem Cell Approaches for Treatment of Neurodegenerative Diseases. <i>Clinical Pharmacology &amp; Biopharmaceutics</i> , 2014, 3, .	0.2	0
31	AMINO ACID TRANSPORTERS IN DRUG DISCOVERY. <i>Current Research in Drug Discovery</i> , 2014, 1, 1-16.	0.4	0
33	Endogenous and synthetic MMP inhibitors in CNS physiopathology. <i>Progress in Brain Research</i> , 2014, 214, 313-351.	0.9	39
34	Diffuse intrinsic pontine glioma: time for therapeutic optimism. <i>CNS Oncology</i> , 2014, 3, 337-348.	1.2	8
35	In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 4007-4026.	2.4	42
36	BBB-conquering antibodies. <i>Science-Business EXchange</i> , 2014, 7, 104-104.	0.0	0
37	Cationic Polymers as Carriers through the Blood-brain Barrier. <i>RSC Polymer Chemistry Series</i> , 2014, , 539-556.	0.1	2
38	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. <i>Frontiers in Pharmacology</i> , 2014, 5, 231.	1.6	136
39	Barriers to Drug Delivery for Brain Trauma. , 2014, , 125-140.		1
40	Endosomes: guardians against [Ru(Phen) <sub>3</sub> ] <sup>2+</sup> photo-action in endothelial cells during in vivo pO <sub>2</sub> detection?. <i>Metallomics</i> , 2014, 6, 2279-2289.	1.0	10

#	ARTICLE	IF	CITATIONS
41	Role of the Bloodâ€“Brain Barrier in Multiple Sclerosis. Archives of Medical Research, 2014, 45, 687-697.	1.5	261
42	Role of the Bloodâ€“Brain Barrier in the Nutrition of the Central Nervous System. Archives of Medical Research, 2014, 45, 610-638.	1.5	137
43	Engineered Cell Manipulation for Biomedical Application. Nanomedicine and Nanotoxicology, 2014, , .	0.1	3
44	Cyclodextrins, Bloodâ€“Brain Barrier, and Treatment of Neurological Diseases. Archives of Medical Research, 2014, 45, 711-729.	1.5	79
45	Development of 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neuroscience Bulletin, 2014, 30, 777-811.	1.5	46
46	Designing the future of nanomedicine: current barriers to targeted brain therapeutics. European Journal of Nanomedicine, 2014, 6, .	0.6	17
47	<i>Carthamus</i> , <i>Salvia</i> and <i>Stachys</i> species protect neuronal cells against oxidative stress-induced apoptosis. Pharmaceutical Biology, 2014, 52, 1550-1557.	1.3	25
48	Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives. British Journal of Pharmacology, 2014, 171, 837-848.	2.7	66
49	Regenerative Therapies for Central Nervous System Diseases: a Biomaterials Approach. Neuropsychopharmacology, 2014, 39, 169-188.	2.8	248
50	Quantitative targeted proteomics for understanding the bloodâ€“brain barrier: towards pharmacoproteomics. Expert Review of Proteomics, 2014, 11, 303-313.	1.3	38
51	Biodistribution of rhodamine B fluorescence-labeled cationic nanoparticles in rats. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	14
52	Strategies To Deliver Peptide Drugs to the Brain. Molecular Pharmaceutics, 2014, 11, 1081-1093.	2.3	133
53	From Gut to Brain: Bioencapsulated Therapeutic Protein Reduces Amyloid Load Upon Oral Delivery. Molecular Therapy, 2014, 22, 485-486.	3.7	13
54	Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides, 2014, 57, 78-94.	1.2	226
55	Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo Studies. Pharmaceutical Research, 2014, 31, 1275-1289.	1.7	59
56	Engineered antibodies for molecular imaging of cancer. Methods, 2014, 65, 139-147.	1.9	139
57	Neural Signatures of Modified Memories. Neuron, 2014, 81, 3-5.	3.8	1
58	Breaching the Blood-Brain Barrier for Drug Delivery. Neuron, 2014, 81, 1-3.	3.8	75

#	ARTICLE	IF	CITATIONS
59	Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. <i>Neuron</i> , 2014, 81, 49-60.	3.8	427
60	Brain Uptake of a Fluorescent Vector Targeting the Transferrin Receptor: A Novel Application of <i>in Situ</i> Brain Perfusion. <i>Molecular Pharmaceutics</i> , 2014, 11, 243-253.	2.3	33
61	Inhibition of Monocyte Adhesion to Brain-Derived Endothelial Cells by Dual Functional RNA Chimeras. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e209.	2.3	11
62	The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. <i>Therapeutic Delivery</i> , 2014, 5, 709-733.	1.2	220
63	Delivery of Therapeutic Peptides and Proteins to the CNS. <i>Advances in Pharmacology</i> , 2014, 71, 277-299.	1.2	34
64	Frizzled Fissure to Improve Central Nervous System Drug Delivery?. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1257-1257.	2.4	2
65	The Size of Blood-Brain Barrier Opening Induced by Focused Ultrasound is Dictated by the Acoustic Pressure. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1197-1204.	2.4	205
66	Neuropharmacokinetics of two investigational compounds in rats: Divergent temporal profiles in the brain and cerebrospinal fluid. <i>Biochemical Pharmacology</i> , 2014, 91, 543-551.	2.0	11
67	Functional Expression of Drug Transporters in Glial Cells. <i>Advances in Pharmacology</i> , 2014, 71, 45-111.	1.2	28
68	Blood-brain barrier (BBB) toxicity and permeability assessment after L-(4- <sup>10</sup> Boronophenyl)alanine, a conventional B-containing drug for boron neutron capture therapy, using an <i>in vitro</i> BBB model. <i>Brain Research</i> , 2014, 1583, 34-44.	1.1	7
69	Physiology and Pathophysiology of Cerebral Microcirculation. , 2014, , 1-31.		0
70	Insulin Receptor Antibody-Sulfamidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosaminoglycans in Sanfilippo Type A Cells. <i>Molecular Pharmaceutics</i> , 2014, 11, 2928-2934.	2.3	58
71	Oral Delivery of Bioencapsulated Proteins Across Blood-Brain and Blood-Retinal Barriers. <i>Molecular Therapy</i> , 2014, 22, 535-546.	3.7	70
72	Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. <i>Nanotechnology</i> , 2014, 25, 055101.	1.3	102
73	Shuttle-Cargo Fusion Molecules of Transport Peptides and the hD <sub>2/3</sub> Receptor Antagonist Fallypride: A Feasible Approach To Preserve Ligand-Receptor Binding?. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4368-4381.	2.9	7
74	Layered double hydroxide nanocomposite for drug delivery systems; bio-distribution, toxicity and drug activity enhancement. <i>Chemistry Central Journal</i> , 2014, 8, 47.	2.6	66
75	Classics in Chemical Neuroscience: Levodopa. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1192-1197.	1.7	44
76	Drug delivery across the blood-brain barrier using focused ultrasound. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 711-721.	2.4	79

#	ARTICLE	IF	CITATIONS
77	Precision Nanomedicine in Neurodegenerative Diseases. ACS Nano, 2014, 8, 1958-1965.	7.3	95
78	Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine. Neuropharmacology, 2014, 87, 125-134.	2.0	36
79	mRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neuroscience Letters, 2014, 559, 99-104.	1.0	21
80	Endophilin-1 regulates blood-brain barrier permeability by controlling ZO-1 and occludin expression via the EGFR-ERK1/2 pathway. Brain Research, 2014, 1573, 17-26.	1.1	60
82	Pathways for Small Molecule Delivery to the Central Nervous System across the Blood-Brain Barrier. Perspectives in Medicinal Chemistry, 2014, 6, PMC.S13384.	4.6	138
83	Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice. Journal of Visualized Experiments, 2014, , .	0.2	3
86	Morphological and Functional Properties of the Blood-Brain Barrier. , 2015, , 1-50.		2
87	FNDC5/Irisin - Their Role in the Nervous System and as a Mediator for Beneficial Effects of Exercise on the Brain. Brain Plasticity, 2015, 1, 55-61.	1.9	98
88	Physiochemical basis of human degenerative disease. Interdisciplinary Toxicology, 2015, 8, 15-21.	1.0	15
90	A Peptide Ligand of Nicotine Acetylcholine Receptors for Brain-Targeted Drug Delivery. Angewandte Chemie, 2015, 127, 3066-3070.	1.6	14
91	Immunoliposomes doubly targeted to transferrin receptor and to $\alpha$ -synuclein. Future Science OA, 2015, 1, FSO71.	0.9	18
92	Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases. Journal of Peptide Science, 2015, 21, 379-386.	0.8	32
93	Self-assembled penetratin-deferasirox micelles as potential carriers for hydrophobic drug delivery. Biopolymers, 2015, 104, 712-719.	1.2	14
94	Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment. Journal of Drug Delivery, 2015, 2015, 1-15.	2.5	19
95	Deposition pattern and subcellular distribution of disease-associated prion protein in cerebellar organotypic slice cultures infected with scrapie. Frontiers in Neuroscience, 2015, 9, 410.	1.4	10
96	Permeation of Dopamine Sulfate through the Blood-Brain Barrier. PLoS ONE, 2015, 10, e0133904.	1.1	14
97	Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness. International Journal of Nanomedicine, 2015, 10, 3245.	3.3	42
99	Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opinion on Therapeutic Targets, 2015, 19, 1059-1072.	1.5	108

#	ARTICLE	IF	CITATIONS
100	Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 336-346.	2.3	104
101	Therapeutic Applications of Spherical Nucleic Acids. <i>Cancer Treatment and Research</i> , 2015, 166, 23-50.	0.2	32
103	Exosomes as drug delivery vehicles for Parkinson's disease therapy. <i>Journal of Controlled Release</i> , 2015, 207, 18-30.	4.8	1,363
104	Des-acyl ghrelin attenuates pilocarpine-induced limbic seizures via the ghrelin receptor and not the orexin pathway. <i>Neuropeptides</i> , 2015, 51, 1-7.	0.9	17
105	Drug Permeation across the Blood-Brain Barrier: Applications of Nanotechnology. <i>British Journal of Medicine and Medical Research</i> , 2015, 6, 547-556.	0.2	17
106	Focused ultrasound-mediated drug delivery through the blood-brain barrier. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 477-491.	1.4	181
107	The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 741-752.	1.4	221
108	Targeted delivery of protein and gene medicines through the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 347-361.	2.3	98
109	Mass Spectrometry Imaging in Drug Development. <i>Analytical Chemistry</i> , 2015, 87, 1437-1455.	3.2	153
110	Discovery of anthranilamides as a novel class of inhibitors of neurotropic alphavirus replication. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1569-1587.	1.4	9
111	Relevance of Blood-Brain Barrier Disruption After Endovascular Treatment of Ischemic Stroke. <i>Stroke</i> , 2015, 46, 673-679.	1.0	96
112	Learning from our failures in blood-brain permeability: what can be done for new drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 207-211.	2.5	4
113	Anatomy and physiology of the blood-brain barrier. <i>Seminars in Cell and Developmental Biology</i> , 2015, 38, 2-6.	2.3	286
114	Cerebral Microcirculation: An Introduction. , 2015, , 655-680.		2
115	What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 15-21.	4.0	46
116	Cardioprotective Cryptides Derived from Fish and Other Food Sources: Generation, Application, and Future Markets. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 1319-1331.	2.4	32
117	A Peptide Ligand of Nicotine Acetylcholine Receptors for Brain-Targeted Drug Delivery. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 3023-3027.	7.2	141
118	Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules. <i>International Journal of Energy Production and Management</i> , 2015, 2, 31-45.	1.9	133

#	ARTICLE	IF	CITATIONS
119	Peptide Nanofiber Complexes with siRNA for Deep Brain Gene Silencing by Stereotactic Neurosurgery. <i>ACS Nano</i> , 2015, 9, 1137-1149.	7.3	41
120	Selective binding to monoamine oxidase A: In vitro and in vivo evaluation of 18F-labeled $\beta^2$ -carboline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 612-623.	1.4	15
121	Permeability of the Blood–Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds. <i>Journal of Membrane Biology</i> , 2015, 248, 651-669.	1.0	93
122	Drug Transporters in the Central Nervous System. <i>Clinical Pharmacokinetics</i> , 2015, 54, 225-242.	1.6	43
123	Blood–brain barrier permeable anticholinesterase auroones: Synthesis, structure–activity relationship, and drug-like properties. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 195-210.	2.6	40
124	Remote control of the permeability of the blood–brain barrier by magnetic heating of nanoparticles: A proof of concept for brain drug delivery. <i>Journal of Controlled Release</i> , 2015, 206, 49-57.	4.8	118
126	A balanced view of choroid plexus structure and function: Focus on adult humans. <i>Experimental Neurology</i> , 2015, 267, 78-86.	2.0	167
127	Lysosomal storage disease: Gene therapy on both sides of the blood–brain barrier. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 83-93.	0.5	45
128	Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. <i>Chemical Society Reviews</i> , 2015, 44, 7737-7763.	18.7	175
129	Halogenated Natural Products in Dolphins: Brain–Blubber Distribution and Comparison with Halogenated Flame Retardants. <i>Environmental Science &amp; Technology</i> , 2015, 49, 9073-9083.	4.6	36
130	Intriguing possibilities and beneficial aspects of transporter-conscious drug design. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4119-4131.	1.4	25
131	Visualization of Time-Dependent Distribution of Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS. <i>Assay and Drug Development Technologies</i> , 2015, 13, 277-284.	0.6	25
132	Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 78, 54-66.	1.9	177
133	Movement of magnetic nanoparticles in brain tissue: mechanisms and impact on normal neuronal function. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1821-1829.	1.7	48
134	Nepriylisin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. <i>European Heart Journal</i> , 2015, 36, 902-905.	1.0	61
135	Molecular fMRI. , 2015, , 123-129.		5
136	Safety Pharmacology Evaluation of Biopharmaceuticals. <i>Handbook of Experimental Pharmacology</i> , 2015, 229, 385-404.	0.9	3
137	Recent advances in silicon-based neural microelectrodes and microsystems: a review. <i>Sensors and Actuators B: Chemical</i> , 2015, 215, 300-315.	4.0	80



#	ARTICLE	IF	CITATIONS
138	Acute oral toxicity and biodistribution study of zinc-aluminium-levodopa nanocomposite. <i>Nanoscale Research Letters</i> , 2015, 10, 105.	3.1	20
139	Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. <i>Drug Resistance Updates</i> , 2015, 19, 1-12.	6.5	706
140	Transport Mechanisms of Squalenoyl-Adenosine Nanoparticles Across the Blood-Brain Barrier. <i>Chemistry of Materials</i> , 2015, 27, 3636-3647.	3.2	32
141	Neuronal and Vascular Interactions. <i>Annual Review of Neuroscience</i> , 2015, 38, 25-46.	5.0	200
142	The Molecular Constituents of the Blood-Brain Barrier. <i>Trends in Neurosciences</i> , 2015, 38, 598-608.	4.2	281
143	Toward nonsystemic delivery of therapeutics across the blood-brain barrier. <i>Nanomedicine</i> , 2015, 10, 2129-2131.	1.7	3
144	Penetrating the Blood-Brain Barrier: Promise of Novel Nanoplatfoms and Delivery Vehicles. <i>ACS Nano</i> , 2015, 9, 9470-9474.	7.3	76
145	Nanoparticle delivery to the brain by focused ultrasound and self-assembled nanoparticle-stabilized microbubbles. <i>Journal of Controlled Release</i> , 2015, 220, 287-294.	4.8	57
146	An introduction to MS imaging in drug discovery and development. <i>Bioanalysis</i> , 2015, 7, 2621-2627.	0.6	4
147	Conformation and interactions of dopamine hydrochloride in solution. <i>Journal of Chemical Physics</i> , 2015, 142, 014502.	1.2	16
148	Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. <i>Journal of Drug Targeting</i> , 2015, 23, 736-749.	2.1	73
149	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	0.9	22
150	Nano-enabled delivery of diverse payloads across complex biological barriers. <i>Journal of Controlled Release</i> , 2015, 219, 548-559.	4.8	54
151	Analytical challenges for measuring steroid responses to stress, neurodegeneration and injury in the central nervous system. <i>Steroids</i> , 2015, 103, 42-57.	0.8	35
152	Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. <i>Pharmaceutical Research</i> , 2015, 32, 3432-3446.	1.7	9
153	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1889-1894.	0.8	88
154	Nanomedicines and stroke: Toward translational research. <i>Journal of Drug Delivery Science and Technology</i> , 2015, 30, 278-299.	1.4	12
155	An LC/MS quantitative and microdialysis method for cyclovirobuxine D pharmacokinetics in rat plasma and brain: The pharmacokinetic comparison of three different drug delivery routes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 185-193.	1.2	15

#	ARTICLE	IF	CITATIONS
156	Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. <i>Therapeutic Delivery</i> , 2015, 6, 989-1016.	1.2	48
157	Challenges and new strategies for therapeutic peptide delivery to the CNS. <i>Therapeutic Delivery</i> , 2015, 6, 841-853.	1.2	10
158	Transthyretin as a new transporter of nanoparticles for receptor-mediated transcytosis in rat brain microvessels. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 136, 989-996.	2.5	15
159	Hydrogels for central nervous system therapeutic strategies. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2015, 229, 905-916.	1.0	14
160	Novel delivery methods bypassing the blood-brain and blood-tumor barriers. <i>Neurosurgical Focus</i> , 2015, 38, E10.	1.0	84
161	Penetration of Treosulfan and its Active Monoepoxide Transformation Product into Central Nervous System of Juvenile and Young Adult Rats. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1946-1954.	1.7	10
162	Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance. <i>Pharmaceutical Research</i> , 2015, 32, 1161-1185.	1.7	90
163	In silico methods to identify meat-derived prolyl endopeptidase inhibitors. <i>Food Chemistry</i> , 2015, 175, 337-343.	4.2	66
164	Development of reversible glutamine conjugate of methotrexate for enhanced brain delivery. <i>Medicinal Chemistry Research</i> , 2015, 24, 624-635.	1.1	16
165	Phenylketonuria: Brain Phenylalanine Concentrations Relate Inversely to Cerebral Protein Synthesis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 200-205.	2.4	16
166	Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 207-222.	2.4	127
167	Increase of Zinc Finger Protein 179 in Response to CCAAT/Enhancer Binding Protein Delta Conferring an Antiapoptotic Effect in Astrocytes of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 370-382.	1.9	37
169	The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?. <i>F1000Research</i> , 2016, 5, 313.	0.8	104
170	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APP <sup>SwDI</sup> /NOS2 <sup>-/-</sup> Mouse Model. <i>Current Alzheimer Research</i> , 2016, 13, 663-677.	0.7	13
171	Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice. <i>Journal of Nuclear Medicine &amp; Radiation Therapy</i> , 2016, 7, .	0.2	3
172	Choroid Plexus: Structure and Function. , 2016, , 29-40.		9
173	Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain metastases. <i>Translational Lung Cancer Research</i> , 2016, 5, 208-211.	1.3	3
174	Selecting Good "Drug-Like" Properties to Optimize Small Molecule Blood-Brain Barrier Penetration. <i>Current Medicinal Chemistry</i> , 2016, 23, 1392-1407.	1.2	25

#	ARTICLE	IF	CITATIONS
175	Toward an Artificial Choroid Plexus, Concept and Clinical Implications. , 2016, , 41-63.		0
176	Causes, Mechanisms and Prevention of Environmental Diseases. Dual Diagnosis (Foster City), 2016, 01, .	0.0	2
177	Diagnosis and Treatment of Neurological and Ischemic Disorders Employing Carbon Nanotube Technology. Journal of Nanomaterials, 2016, 2016, 1-19.	1.5	24
178	Anti-Inflammation of Natural Components from Medicinal Plants at Low Concentrations in Brain via Inhibiting Neutrophil Infiltration after Stroke. Mediators of Inflammation, 2016, 2016, 1-12.	1.4	7
179	Recovery, rehabilitation, and repair. , 0, , 608-626.		0
180	Central Nervous System Penetration of the Opioid Oxycodone. , 2016, , 457-466.		6
181	Blood-brain barrier transport machineries and targeted therapy of brain diseases. BiolImpacts, 2016, 6, 225-248.	0.7	174
182	Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Current Pharmaceutical Design, 2016, 22, 1177-1193.	0.9	240
183	Lactate as a Metabolite and a Regulator in the Central Nervous System. International Journal of Molecular Sciences, 2016, 17, 1450.	1.8	174
184	Microfabricated Physiological Models for In Vitro Drug Screening Applications. Micromachines, 2016, 7, 233.	1.4	19
185	BioPPSy: An Open-Source Platform for QSAR/QSPR Analysis. PLoS ONE, 2016, 11, e0166298.	1.1	11
186	Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. International Journal of Molecular Sciences, 2016, 17, 1463.	1.8	33
187	Organic anion transporting polypeptide 2 transports valproic acid in rat brain microvascular endothelial cells. Neurological Research, 2016, 38, 634-639.	0.6	13
188	Pharmacological Effects of a Monoclonal Antibody against 6-Monoacetylmorphine upon Heroin-Induced Locomotor Activity and Pharmacokinetics in Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 181-189.	1.3	16
189	Neural Engineering. , 2016, , .		8
190	Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. Stem Cells, 2016, 34, 2016-2025.	1.4	9
191	In Vitro Modeling of Nervous System: Engineering of the Reflex Arc. , 2016, , 261-298.		1
192	Hyperthermia of magnetic nanoparticles allows passage of sodium fluorescein and Evans blue dye across the bloodâ€“retinal barrier. International Journal of Hyperthermia, 2016, 32, 657-665.	1.1	16

#	ARTICLE	IF	CITATIONS
193	Into rather unexplored terrainâ€”transcellular transport across the bloodâ€”brain barrier. <i>Glia</i> , 2016, 64, 1097-1123.	2.5	118
194	Drug Repurposing to Circumvent Chemotherapy Resistance in Brain Tumours. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 107-144.	0.1	3
195	Resistance to Targeted Therapies Against Adult Brain Cancers. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	4
196	An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles. <i>Scientific Reports</i> , 2016, 6, 22595.	1.6	34
197	Characterization of the diffusion process of different Gadolinium-based nanoparticles within the brain tissue after ultrasound induced Blood-Brain Barrier permeabilization. , 2016, , .		4
199	Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes. <i>BMC Genomics</i> , 2016, 17, 516.	1.2	17
200	Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier. <i>Scientific Reports</i> , 2016, 6, 25658.	1.6	70
201	MiniApe4: A Venomâ€”inspired Peptidomimetic for Brain Delivery. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 572-575.	7.2	66
202	Regeneration strategies after the adult mammalian central nervous system injuryâ€”biomaterials. <i>International Journal of Energy Production and Management</i> , 2016, 3, 115-122.	1.9	11
203	Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. <i>Biomaterials</i> , 2016, 101, 96-107.	5.7	107
204	Bloodâ€”brain barrier shuttle peptides: an emerging paradigm for brain delivery. <i>Chemical Society Reviews</i> , 2016, 45, 4690-4707.	18.7	318
206	Pharmacokinetic Properties. , 2016, , 3-27.		1
207	Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. <i>Chemical Reviews</i> , 2016, 116, 5338-5431.	23.0	1,333
208	Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1237-1245.	1.5	43
209	The bloodâ€”brain barrier. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 39-59.	1.0	152
210	Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the bloodâ€”brain barrier. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 104, 148-155.	2.0	84
211	Overview of Polyester Nanosystems for Nasal Administration. , 2016, , 291-351.		1
212	Gadolinium deposition in the brain: Lessons learned from other metals known to cross the bloodâ€”brain barrier. <i>Magnetic Resonance Imaging</i> , 2016, 34, 1366-1372.	1.0	18

#	ARTICLE	IF	CITATIONS
213	Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. <i>Journal of Neuroinflammation</i> , 2016, 13, 236.	3.1	89
214	Accumulation of polybrominated diphenyl ethers in the brain compared with the levels in other tissues among different vertebrates from an e-waste recycling site. <i>Environmental Pollution</i> , 2016, 218, 1334-1341.	3.7	27
215	Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 79, 360-369.	1.2	200
217	Rescue of mitochondrial function in -mutant fibroblasts using drug loaded PMPC-PDPA polymersomes and tubular polymersomes. <i>Neuroscience Letters</i> , 2016, 630, 23-29.	1.0	7
218	The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex. <i>Paediatric Anaesthesia</i> , 2016, 26, 109-111.	0.6	15
219	Elucidation of Exosome Migration Across the Blood-Brain Barrier Model In Vitro. <i>Cellular and Molecular Bioengineering</i> , 2016, 9, 509-529.	1.0	368
220	Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1455-1468.	1.4	49
221	Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy. <i>Small</i> , 2016, 12, 5108-5119.	5.2	82
222	Large neutral amino acids levels in primate cerebrospinal fluid do not confirm competitive transport under baseline conditions. <i>Brain Research</i> , 2016, 1648, 372-379.	1.1	6
223	Chloro-aluminium phthalocyanine loaded in ultradeformable liposomes for photobiology studies on human glioblastoma. <i>RSC Advances</i> , 2016, 6, 79631-79640.	1.7	16
224	Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Critical Care</i> , 2016, 20, 343.	2.5	47
225	Characterizing Focused-Ultrasound Mediated Drug Delivery to the Heterogeneous Primate Brain In Vivo with Acoustic Monitoring. <i>Scientific Reports</i> , 2016, 6, 37094.	1.6	52
226	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016, 22, 5130-5140.	3.2	554
227	Neuron-Targeted Nanoparticle for siRNA Delivery to Traumatic Brain Injuries. <i>ACS Nano</i> , 2016, 10, 7926-7933.	7.3	110
228	Ocular disposition of treosulfan and its active epoxy-transformers following intravenous administration in rabbits. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 356-362.	1.1	4
229	Minimum Transendothelial Electrical Resistance Thresholds for the Study of Small and Large Molecule Drug Transport in a Human <i>in Vitro</i> Blood-Brain Barrier Model. <i>Molecular Pharmaceutics</i> , 2016, 13, 4191-4198.	2.3	72
230	Targeted Therapy for Malignant Brain Tumors. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 433-450.	0.4	0
231	Exploring tight junction alteration using double fluorescent probe combination of lanthanide complex with gold nanoclusters. <i>Scientific Reports</i> , 2016, 6, 32218.	1.6	11

#	ARTICLE	IF	CITATIONS
232	In vitro characterization of pralidoxime transport and acetylcholinesterase reactivation across MDCK cells and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs). <i>Fluids and Barriers of the CNS</i> , 2016, 13, 10.	2.4	19
233	Cognitive Effects of Nutraceuticals. , 2016, , 29-48.		1
234	Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. <i>Drug Delivery</i> , 2016, 23, 2327-2337.	2.5	28
235	Medicinal plants in Brazil: Pharmacological studies, drug discovery, challenges and perspectives. <i>Pharmacological Research</i> , 2016, 112, 4-29.	3.1	250
236	Genetic manipulation of brain endothelial cells in vivo. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 381-394.	1.8	15
237	Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. <i>Biomaterials</i> , 2016, 83, 257-268.	5.7	46
238	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
239	CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. <i>Neurobiology of Disease</i> , 2016, 88, 118-124.	2.1	35
240	ABC Transporters - 40 Years on. , 2016, , .		17
241	Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer. <i>Nanomedicine</i> , 2016, 11, 171-187.	1.7	21
242	Targeting specific cells in the brain with nanomedicines for CNS therapies. <i>Journal of Controlled Release</i> , 2016, 240, 212-226.	4.8	71
243	Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. <i>Journal of Controlled Release</i> , 2016, 240, 443-453.	4.8	47
244	Structural Insights into the Transport Mechanism of the Human Sodium-dependent Lysophosphatidylcholine Transporter MFSD2A. <i>Journal of Biological Chemistry</i> , 2016, 291, 9383-9394.	1.6	61
245	Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 103, 62-70.	2.0	8
246	Dendrimer technologies for brain tumor. <i>Drug Discovery Today</i> , 2016, 21, 766-778.	3.2	81
247	Ultrasound treatment of neurological diseases – current and emerging applications. <i>Nature Reviews Neurology</i> , 2016, 12, 161-174.	4.9	200
248	Quantitative structure retention/activity relationships of biologically relevant 4-amino-7-chloroquinoline based compounds. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 144-152.	1.2	12
249	Interventions to Improve Recovery after Stroke. , 2016, , 972-980.e5.		4

#	ARTICLE	IF	CITATIONS
250	Neurotrophic activity of jiadifenolide on neuronal precursor cells derived from human induced pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 798-803.	1.0	16
251	Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. <i>Journal of Controlled Release</i> , 2016, 227, 23-37.	4.8	193
252	The challenges associated with molecular targeted therapies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 427-434.	1.4	58
253	Stem Cell-Based Human Bloodâ€“Brain Barrier Models for Drug Discovery and Delivery. <i>Trends in Biotechnology</i> , 2016, 34, 382-393.	4.9	137
254	â€œTastingâ€•the cerebrospinal fluid: Another function of the choroid plexus?. <i>Neuroscience</i> , 2016, 320, 160-171.	1.1	32
255	Localization and mobility of glucose-coated gold nanoparticles within the brain. <i>Nanomedicine</i> , 2016, 11, 617-625.	1.7	28
256	Molecular Architecture of the Blood Brain Barrier Tight Junction Proteinsâ€“A Synergistic Computational and <i>In Vitro</i> Approach. <i>Journal of Physical Chemistry B</i> , 2016, 120, 77-88.	1.2	46
257	Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies. <i>International Journal of Pharmaceutics</i> , 2016, 503, 127-140.	2.6	59
258	Nanoparticle transport across the blood brain barrier. <i>Tissue Barriers</i> , 2016, 4, e1153568.	1.6	121
259	Characterization of passive permeability at the bloodâ€“tumor barrier in five preclinical models of brain metastases of breast cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 373-383.	1.7	45
260	Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 287-296.	5.7	949
261	Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain. <i>Journal of Controlled Release</i> , 2016, 224, 69-76.	4.8	29
262	Kinetics of functionalised carbon nanotube distribution in mouse brain after systemic injection: Spatial to ultra-structural analyses. <i>Journal of Controlled Release</i> , 2016, 224, 22-32.	4.8	48
263	Aptamers as radiopharmaceuticals for nuclear imaging and therapy. <i>Nuclear Medicine and Biology</i> , 2016, 43, 253-271.	0.3	49
264	Microbubble-Assisted Ultrasound for Drug Delivery in the Brain and Central Nervous System. <i>Advances in Experimental Medicine and Biology</i> , 2016, 880, 293-308.	0.8	41
265	On the atomic structure of cocaine in solution. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 991-999.	1.3	23
266	Progesterone neuroprotection: The background of clinical trial failure. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 160, 53-66.	1.2	77
267	MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA. <i>Neuro-Oncology</i> , 2016, 18, 691-699.	0.6	48

#	ARTICLE	IF	CITATIONS
268	Strategies to target drugs to gliomas and CNS metastases of solid tumors. <i>Journal of Neurology</i> , 2016, 263, 428-440.	1.8	14
269	3 $\beta$ -Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv112.	1.0	22
270	Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2016, 55, 297-311.	1.6	44
271	Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. <i>Clinical Pharmacokinetics</i> , 2016, 55, 143-167.	1.6	21
272	Drug delivery approaches for the treatment of glioblastoma multiforme. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1365-1373.	1.9	36
273	A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells. <i>Drug Delivery</i> , 2016, 23, 2464-2470.	2.5	16
274	Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery. <i>Molecular Neurobiology</i> , 2017, 54, 1046-1077.	1.9	241
275	The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. <i>Neuropharmacology</i> , 2017, 120, 11-19.	2.0	239
276	Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-art, challenges, and opportunities for studying brain chemistry. <i>Human Brain Mapping</i> , 2017, 38, 2276-2325.	1.9	57
277	Positional isomers of bispyridine benzene derivatives induce efficacy changes on mGlu5 negative allosteric modulation. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 567-576.	2.6	14
278	Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 130-143.	2.0	50
279	Three-dimensional aligned nanofibers-hydrogel scaffold for controlled non-viral drug/gene delivery to direct axon regeneration in spinal cord injury treatment. <i>Scientific Reports</i> , 2017, 7, 42212.	1.6	141
280	Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis. <i>Neuron</i> , 2017, 94, 581-594.e5.	3.8	401
281	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1267-1271.	1.1	5
282	Neurotrophic Factors Used to Treat Spinal Cord Injury. <i>Vitamins and Hormones</i> , 2017, 104, 405-457.	0.7	54
283	Hypoxic-Ischaemic Encephalopathy and the Blood-Brain Barrier in Neonates. <i>Developmental Neuroscience</i> , 2017, 39, 49-58.	1.0	49
284	Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier. <i>Cell Stem Cell</i> , 2017, 20, 831-843.e5.	5.2	181
285	Pharmacokinetic and pharmacodynamic alterations in older people with dementia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 651-668.	1.5	55



#	ARTICLE	IF	CITATIONS
286	Fibronectin-adherent peripheral blood derived mononuclear cells as Paclitaxel carriers for glioblastoma treatment: An in vitro study. <i>Cytotherapy</i> , 2017, 19, 721-734.	0.3	9
287	On the structure of prilocaine in aqueous and amphiphilic solutions. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 12665-12673.	1.3	4
288	Zebrafish as a visual and dynamic model to study the transport of nanosized drug delivery systems across the biological barriers. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 156, 227-235.	2.5	37
289	Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery. <i>Journal of Controlled Release</i> , 2017, 261, 43-61.	4.8	44
290	1-(2,4-Dibromophenyl)-3,6,6-trimethyl-1,5,6,7-tetrahydro-4 <i>H</i> -indazol-4-one. <i>Anesthesiology</i> , 2017, 126, 952-966.	1.3	5
291	L-Borneol induces transient opening of the blood-brain barrier and enhances the therapeutic effect of cisplatin. <i>NeuroReport</i> , 2017, 28, 506-513.	0.6	39
292	Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy. <i>AAPS Journal</i> , 2017, 19, 973-988.	2.2	64
293	Functional Expression of P-glycoprotein and Organic Anion Transporting Polypeptides at the Blood-Brain Barrier: Understanding Transport Mechanisms for Improved CNS Drug Delivery?. <i>AAPS Journal</i> , 2017, 19, 931-939.	2.2	61
294	Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1570-1576.	1.7	100
295	Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2467-2485.	2.4	12
297	Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 4, 204-212.	1.8	12
298	Pharmaceutical Characterization of Tropomyosin Receptor Kinase B-Agonistic Antibodies on Human Induced Pluripotent Stem (hiPS) Cell-Derived Neurons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 355-365.	1.3	14
299	Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 180-187.	1.9	41
300	On the hydration and conformation of cocaine in solution. <i>Chemical Physics Letters</i> , 2017, 676, 58-64.	1.2	4
301	Exosomes in Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2017, 33, 331-338.	1.5	97
302	Novel Delivery Strategies. , 2017, , 193-216.		0
303	Carbohydrate-Neuroactive Hybrid Strategy for Metabolic Glycan Engineering of the Central Nervous System <i>in Vivo</i> . <i>Journal of the American Chemical Society</i> , 2017, 139, 693-700.	6.6	26
304	Omega-3 polyunsaturated fatty acids and brain health: Preclinical evidence for the prevention of neurodegenerative diseases. <i>Trends in Food Science and Technology</i> , 2017, 69, 203-213.	7.8	50

#	ARTICLE	IF	CITATIONS
305	Peptides and Drug Delivery. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1030, 167-184.	0.8	12
306	Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke. <i>Journal of Central Nervous System Disease</i> , 2017, 9, 117957351769380.	0.7	53
307	Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach. <i>Clinical Cancer Research</i> , 2017, 23, 7454-7466.	3.2	44
308	Organs-on-a-chip. <i>Toxicology Research and Application</i> , 2017, 1, 239784731772635.	0.7	21
309	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 2579-2595.	1.7	30
310	Regulation of Reduced Folate Carrier (RFC) by Vitamin D Receptor at the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2017, 14, 3848-3858.	2.3	36
311	A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol. <i>Scientific Reports</i> , 2017, 7, 9447.	1.6	8
312	Noninvasive nanoparticle strategies for brain tumor targeting. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 2605-2621.	1.7	57
313	Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
314	Blood purine measurements as a rapid real-time indicator of reversible brain ischaemia. <i>Purinergic Signalling</i> , 2017, 13, 521-528.	1.1	25
315	Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma. <i>Materials Horizons</i> , 2017, 4, 977-996.	6.4	14
316	Receptor Targeted Polymeric Nanostructures Capable of Navigating across the Blood-Brain Barrier for Effective Delivery of Neural Therapeutics. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2105-2117.	1.7	14
317	Patents Survey: Treatment of Alzheimer's Disease Through Nanotechnology-Based Drug Delivery System. , 2017, , 335-359.		1
318	Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model. <i>Scientific Reports</i> , 2017, 7, 14372.	1.6	35
319	Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. <i>Biomaterials</i> , 2017, 142, 1-12.	5.7	411
320	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 695-707.	12.5	90
321	SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. <i>AAPS Journal</i> , 2017, 19, 1317-1331.	2.2	104
322	Nanobiomaterials™ applications in neurodegenerative diseases. <i>Journal of Biomaterials Applications</i> , 2017, 31, 953-984.	1.2	44

#	ARTICLE	IF	CITATIONS
323	Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?. <i>BioMetals</i> , 2017, 30, 1-16.	1.8	21
324	Phage display as a tool to discover blood-brain barrier (BBB) shuttle peptides: panning against a human BBB cellular model. <i>Biopolymers</i> , 2017, 108, e22928.	1.2	23
325	Targeting blood-brain-barrier transcytosis perspectives for drug delivery. <i>Neuropharmacology</i> , 2017, 120, 4-7.	2.0	74
326	The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption. <i>Molecular Aspects of Medicine</i> , 2017, 53, 57-72.	2.7	51
327	Targeted brain delivery nanoparticles for malignant gliomas. <i>Nanomedicine</i> , 2017, 12, 59-72.	1.7	32
328	Annexin A1 restores $\text{Al}^{2+}$ -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. <i>Aging Cell</i> , 2017, 16, 149-161.	3.0	87
329	Drug Delivery to the Central Nervous System. , 2017, , 198-201.		3
330	Hereditary folate malabsorption with a novel mutation on SLC46A1. <i>Medicine (United States)</i> , 2017, 96, e8712.	0.4	8
331	Blood-brain barrier development: Systems modeling and predictive toxicology. <i>Birth Defects Research</i> , 2017, 109, 1680-1710.	0.8	50
332	Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. <i>Theranostics</i> , 2017, 7, 308-318.	4.6	146
333	Drug delivery: advancements and challenges. , 2017, , 865-886.		39
334	Diagnosis and Drug Delivery to the Brain. , 2017, , 59-83.		4
335	Drug Delivery to the Brain: Pharmacokinetic Concepts. , 2017, , 69-89.		2
336	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. <i>International Journal of Molecular Sciences</i> , 2017, 18, 768.	1.8	10
337	Ultrasound as a treatment modality for neurological diseases. <i>Medical Journal of Australia</i> , 2017, 206, 470-471.	0.8	1
338	Sepsis-Associated Encephalopathy: The Blood-Brain Barrier and the Sphingolipid Rheostat. <i>Frontiers in Immunology</i> , 2017, 8, 597.	2.2	91
339	Plasma Exosomes Spread and Cluster Around $\text{A}\beta$ -Amyloid Plaques in an Animal Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 12.	1.7	57
340	In Vitro CNS Models. , 2017, , 151-185.		1

#	ARTICLE	IF	CITATIONS
341	Current Perspectives on In Vivo Noninvasive Tracking of Extracellular Vesicles with Molecular Imaging. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	94
343	Drug delivery in overcoming the blood&ndash;brain barrier: role of nasal mucosal grafting. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 325-335.	2.0	35
344	Efficient Enhancement of Blood-Brain Barrier Permeability Using Acoustic Cluster Therapy (ACT). <i>Theranostics</i> , 2017, 7, 23-30.	4.6	34
345	Novel Implications of Exosomes and lncRNAs in the Diagnosis and Treatment of Pancreatic Cancer. , 2017, , .		3
346	Role of Matrix Metalloproteinases in Brain Edema. , 2017, , 199-215.		2
347	Magnetotactic bacteria as micro-carriers of thermal ablation agents. , 2017, , .		0
348	Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity. <i>Cell Death and Disease</i> , 2017, 8, e3102-e3102.	2.7	46
349	ENZYMOSOMES: A RISING EFFECTUAL TOOL FOR TARGETED DRUG DELIVERY SYSTEM. <i>International Journal of Applied Pharmaceutics</i> , 2017, 9, 1.	0.3	15
350	Liposomal Drug Delivery to the Central Nervous System. , 0, , .		6
351	Progesterone: Synthesis, Metabolism, Mechanism of Action, and Effects in the Nervous System. , 2017, , 215-244.		9
352	Y1 receptor ligand-based nanomicelle as a novel nanoprobe for glioma-targeted imaging and therapy. <i>Nanoscale</i> , 2018, 10, 5845-5851.	2.8	14
353	Additional increased effects of mannitol-temozolomide combined treatment on blood-brain barrier permeability. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 769-775.	1.0	18
354	Selective drug delivery approaches to lesioned brain through blood brain barrier disruption. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 335-349.	2.4	21
355	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 110-115.	0.7	12
356	Acylohydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	58
357	The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 292-306.	2.6	60
358	A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. <i>Nuclear Medicine and Biology</i> , 2018, 60, 29-36.	0.3	5
359	Pharmacokinetic profiling of anticancer phytochemicals using computational approach. <i>Phytochemical Analysis</i> , 2018, 29, 559-568.	1.2	16

#	ARTICLE	IF	CITATIONS
360	Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 8916-8935.	1.9	29
361	An overview of hypocretin based therapy in narcolepsy. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 389-406.	1.9	30
362	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1199-1209.	1.9	42
363	The ability of liposomes, tailored for blood-brain barrier targeting, to reach the brain is dramatically affected by the disease state. <i>Nanomedicine</i> , 2018, 13, 585-594.	1.7	11
364	Lordosis facilitated by GPER-1 receptor activation involves GnRH-1, progestin and estrogen receptors in estrogen-primed rats. <i>Hormones and Behavior</i> , 2018, 98, 77-87.	1.0	8
365	Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas. <i>Drug Delivery</i> , 2018, 25, 472-483.	2.5	7
366	Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 133-150.	4.9	1,731
367	Indoloazepinone-Constrained Oligomers as Cell-Penetrating and Blood-Brain-Barrier-Permeating Compounds. <i>ChemBioChem</i> , 2018, 19, 696-705.	1.3	8
368	Granulocyte-colony stimulating factor controls neural and behavioral plasticity in response to cocaine. <i>Nature Communications</i> , 2018, 9, 9.	5.8	213
369	In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain. <i>Journal of Controlled Release</i> , 2018, 273, 108-130.	4.8	43
370	Design and validation of a microfluidic device for blood-brain barrier monitoring and transport studies. <i>Journal of Micromechanics and Microengineering</i> , 2018, 28, 044001.	1.5	16
371	Pharmacoinaging of Blood-Brain Barrier Permeable (FDG) and Impermeable (FLT) Substrates After Intranasal (IN) Administration. <i>AAPS Journal</i> , 2018, 20, 15.	2.2	3
372	Facile construction of dual-targeting delivery system by using lipid capped polymer nanoparticles for anti-glioma therapy. <i>RSC Advances</i> , 2018, 8, 444-453.	1.7	16
373	Overcoming blood-brain barrier by HER2-targeted nanosystem to suppress glioblastoma cell migration, invasion and tumor growth. <i>Journal of Materials Chemistry B</i> , 2018, 6, 568-579.	2.9	30
374	Two-Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2-Positive Breast Cancer. <i>Advanced Functional Materials</i> , 2018, 28, 1705668.	7.8	32
375	Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 825-844.	2.8	85
376	Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step Förster resonance energy transfer imaging. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 261-271.	5.7	35
377	3D tissue engineering, an emerging technique for pharmaceutical research. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 756-766.	5.7	49

#	ARTICLE	IF	CITATIONS
378	Fine-tuning the physicochemical properties of peptide-based bloodâ€“brain barrier shuttles. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2099-2106.	1.4	15
379	Dendrimers as Powerful Building Blocks in Central Nervous System Disease: Headed for Successful Nanomedicine. <i>Advanced Functional Materials</i> , 2018, 28, 1700313.	7.8	29
380	An overview of nanosomes delivery mechanisms: trafficking, orders, barriers and cellular effects. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 669-679.	1.9	29
381	The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 271-291.	4.2	43
382	Nanoparticleâ€“Based Therapeutics for Brain Injury. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700668.	3.9	93
383	Computational Nanotechnology: A Tool for Screening Therapeutic Nanomaterials Against Alzheimerâ€™s Disease. <i>Neuroinformatics</i> , 2018, , 613-635.	0.2	1
384	Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements. <i>Journal of Drug Targeting</i> , 2018, 26, 195-207.	2.1	14
385	Structural and vibrational study of a neurotransmitter molecule: Dopamine [4-(2-aminoethyl) benzene-1,2-diol]. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2018, 189, 473-484.	2.0	28
386	Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation. <i>Molecular Therapy</i> , 2018, 26, 84-94.	3.7	15
387	A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells. <i>International Journal of Pharmaceutics</i> , 2018, 536, 211-221.	2.6	19
388	Peptides as drug delivery vehicles across biological barriers. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 89-111.	2.7	69
389	MEMS devices for drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 128, 132-147.	6.6	61
390	Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment. <i>International Journal of Biological Macromolecules</i> , 2018, 108, 1092-1100.	3.6	59
391	Positron Emission Tomography Assessment of the Intranasal Delivery Route for Orexin A. <i>ACS Chemical Neuroscience</i> , 2018, 9, 358-368.	1.7	21
392	Exosome and MiRNA in Stroke. <i>Springer Series in Translational Stroke Research</i> , 2018, , 325-361.	0.1	1
393	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709.	0.8	359
394	Molecular Probes for Magnetic Resonance Imaging of Amyloid Î² <sup>2</sup> Peptides. , 2018, , .		0
395	Offline encoding impaired by epigenetic regulations of monoamines in the guided propagation model of autism. <i>BMC Neuroscience</i> , 2018, 19, 80.	0.8	5

#	ARTICLE	IF	CITATIONS
396	Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer. <i>BMC Cancer</i> , 2018, 18, 1225.	1.1	12
397	Distribution of superparamagnetic Au/Fe nanoparticles in an isolated guinea pig brain with an intact blood brain barrier. <i>Nanoscale</i> , 2018, 10, 22420-22428.	2.8	10
398	Focused-ultrasound Mediated Anti-Alpha-Synuclein Antibody Delivery for the Treatment of Parkinson's Disease. , 2018, , .		6
399	Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 462.	1.3	108
400	Treatments to Promote Neural Repair after Stroke. <i>Journal of Stroke</i> , 2018, 20, 57-70.	1.4	79
401	Chemical and biological methods for probing the structure and functions of polysialic acids. <i>Emerging Topics in Life Sciences</i> , 2018, 2, 363-376.	1.1	2
402	Exploring the C-terminal Tail Dynamics: Structural and Molecular Perspectives into the Therapeutic Activities of Novel CRMP2 Inhibitors, Naringenin and Naringenin-O-glucuronide, in the Treatment of Alzheimer's Disease. <i>Chemistry and Biodiversity</i> , 2018, 15, e1800437.	1.0	14
403	Focal ultrasound strikes a new tune for targeted drug delivery. <i>Movement Disorders</i> , 2018, 33, 1513-1514.	2.2	0
404	The insight of <i>in vitro</i> and <i>in silico</i> studies on cholinesterase inhibitors from the roots of <i>Cimicifuga dahurica</i> (Turcz.) Maxim.. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 1174-1180.	2.5	11
405	Toward Higher Sensitivity in Quantitative MALDI Imaging Mass Spectrometry of CNS Drugs Using a Nonpolar Matrix. <i>Analytical Chemistry</i> , 2018, 90, 12592-12600.	3.2	20
406	Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiangioma therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 132, 168-179.	2.0	77
407	Scaling behavior of drug transport and absorption in <i>in silico</i> cerebral capillary networks. <i>PLoS ONE</i> , 2018, 13, e0200266.	1.1	2
408	Functional Expression of Organic Anion Transporting Polypeptide 1a4 Is Regulated by Transforming Growth Factor- $\beta$ 2/Activin Receptor-like Kinase 1 Signaling at the Blood-Brain Barrier. <i>Molecular Pharmacology</i> , 2018, 94, 1321-1333.	1.0	21
409	Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia. <i>Scientific Reports</i> , 2018, 8, 15041.	1.6	24
410	Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier. <i>PLoS ONE</i> , 2018, 13, e0205158.	1.1	56
411	Targeted Theranostic Nanoparticles for Brain Tumor Treatment. <i>Pharmaceutics</i> , 2018, 10, 181.	2.0	85
412	Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 309-320.	2.0	64
413	Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach. <i>International Journal of Pharmaceutics</i> , 2018, 551, 339-361.	2.6	19

#	ARTICLE	IF	CITATIONS
414	Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood–brain barrier transport. <i>Chemical Science</i> , 2018, 9, 8409-8415.	3.7	39
415	Efflux Pump Substrates Shuttled to Cytosolic or Vesicular Compartments Exhibit Different Permeability in a Quantitative Human Blood–Brain Barrier Model. <i>Molecular Pharmaceutics</i> , 2018, 15, 5081-5088.	2.3	5
416	Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen. <i>Bioorganic Chemistry</i> , 2018, 81, 494-503.	2.0	18
417	Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	8
418	A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. <i>Fluids and Barriers of the CNS</i> , 2018, 15, 23.	2.4	235
419	Addition of Neostigmine and Atropine to Conventional Management of Postdural Puncture Headache: A Randomized Controlled Trial. <i>Anesthesia and Analgesia</i> , 2018, 127, 1434-1439.	1.1	24
420	Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration. <i>MAbs</i> , 2018, 10, 765-777.	2.6	42
421	<i>In vitro</i> models of molecular and nano-particle transport across the blood-brain barrier. <i>Biomicrofluidics</i> , 2018, 12, 042213.	1.2	61
422	Reconfigurable Nucleic Acid Materials for Cancer Therapy. <i>Nanomedicine and Nanotoxicology</i> , 2018, , 365-385.	0.1	0
423	Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome. <i>Angiogenesis</i> , 2018, 21, 667-675.	3.7	45
424	Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 143-182.	1.0	11
425	Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. <i>Molecular Pharmaceutics</i> , 2018, 15, 3557-3572.	2.3	30
426	Interstitial Chemotherapy and Polymer Drug Delivery. , 2018, , 155-165.		0
427	Evolution of Nanoparticle Protein Corona across the Blood–Brain Barrier. <i>ACS Nano</i> , 2018, 12, 7292-7300.	7.3	137
428	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 171-183.	1.1	17
429	Spherical Nucleic Acid Nanoparticles: Therapeutic Potential. <i>BioDrugs</i> , 2018, 32, 297-309.	2.2	84
430	Neural Repair for Cerebrovascular Diseases. , 2018, , 35-67.		0
431	Blood–brain barrier disruption dictates nanoparticle accumulation following experimental brain injury. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2155-2166.	1.7	29



#	ARTICLE	IF	CITATIONS
432	Synthesis and antimicrobial evaluation of amino sugar-based naphthoquinones and isoquinoline-5,8-diones and their halogenated compounds. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 1-12.	2.6	41
433	Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 2265-2274.	3.3	13
434	Listening in on the Microbubble Crowd: Advanced Acoustic Monitoring for Improved Control of Blood-Brain Barrier Opening with Focused Ultrasound. <i>Theranostics</i> , 2018, 8, 2988-2991.	4.6	25
435	Niosomes decorated with dual ligands targeting brain endothelial transporters increase cargo penetration across the blood-brain barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 228-240.	1.9	38
436	Synthesis, Stability and Relaxivity of TEEPO-Met: An Organic Radical as a Potential Tumour Targeting Contrast Agent for Magnetic Resonance Imaging. <i>Molecules</i> , 2018, 23, 1034.	1.7	11
437	Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1601-1610.	3.3	43
438	Inhibition of VEGF-Flk-1 binding induced profound biochemical alteration in the hippocampus of a rat model of BBB breakdown by spider venom. A preliminary assessment using FT-IR spectroscopy. <i>Neurochemistry International</i> , 2018, 120, 64-74.	1.9	3
439	Role of Physicochemical Parameters on Drug Absorption and Their Implications in Pharmaceutical Product Development. , 2018, , 85-116.		3
440	Harnessing the Potential of Biomaterials for Brain Repair after Stroke. <i>Frontiers in Materials</i> , 2018, 5, .	1.2	31
441	Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice. <i>Frontiers in Neuroscience</i> , 2018, 12, 55.	1.4	50
442	Interfacing Graphene-Based Materials With Neural Cells. <i>Frontiers in Systems Neuroscience</i> , 2018, 12, 12.	1.2	98
443	Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. <i>International Journal of Molecular Sciences</i> , 2018, 19, 406.	1.8	25
444	Design, Synthesis and Characterization of Novel Co-Polymers Decorated with Peptides for the Selective Nanoparticle Transport across the Cerebral Endothelium. <i>Molecules</i> , 2018, 23, 1655.	1.7	18
445	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10345-10374.	2.9	67
446	Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 824.	2.2	77
447	The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. <i>Translational Neurodegeneration</i> , 2018, 7, 5.	3.6	147
448	Bayesian hierarchical modeling of gabapentin absorption and disposition with application to dosing regimen assessment. <i>Computer Aided Chemical Engineering</i> , 2018, , 111-137.	0.3	1
449	Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. <i>Acta Neuropathologica Communications</i> , 2018, 6, 82.	2.4	34

#	ARTICLE	IF	CITATIONS
450	Perspective on the Application of Microphysiological Systems to Drug Transporter Studies. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1647-1657.	1.7	15
451	Effect of the development of a cell barrier on nanoparticle uptake in endothelial cells. <i>Nanoscale</i> , 2018, 10, 16645-16656.	2.8	21
452	2-Hydroxypropyl- $\beta$ -cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1. <i>Current Pharmaceutical Design</i> , 2018, 23, 6231-6238.	0.9	28
453	Phase Engineering of Hydrophobic Meso-Environments in Silica Particles for Technical Performance Enrichment. <i>Langmuir</i> , 2018, 34, 7428-7435.	1.6	3
454	Ultrasound-mediated delivery and distribution of polymeric nanoparticles in the normal brain parenchyma of a metastatic brain tumour model. <i>PLoS ONE</i> , 2018, 13, e0191102.	1.1	39
455	Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from <i>Tussilago farfara</i> . <i>Redox Biology</i> , 2018, 18, 6-15.	3.9	74
456	Biology of the Blood-Brain and Blood-Brain Tumor Barriers. , 2018, , 113-125.		2
457	Liposome-Based Drug Delivery for Brain Tumor Theranostics. , 2018, , 245-266.		3
458	Nanocarriers for the delivery of temozolomide in the treatment of glioblastoma. , 2018, , 687-722.		10
459	Intranasal administration of progesterone: A potential efficient route of delivery for cerebroprotection after acute brain injuries. <i>Neuropharmacology</i> , 2019, 145, 283-291.	2.0	28
460	Envisioning the future of polymer therapeutics for brain disorders. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1532.	3.3	17
461	Magnetic drilling enhances intra-nasal transport of particles into rodent brain. <i>Journal of Magnetism and Magnetic Materials</i> , 2019, 469, 302-305.	1.0	20
462	Biological Characterisation of Somatropin-Derived Cryptic Peptides. <i>International Journal of Peptide Research and Therapeutics</i> , 2019, 25, 1019-1031.	0.9	1
463	The senses of the choroid plexus. <i>Progress in Neurobiology</i> , 2019, 182, 101680.	2.8	17
464	The multiple roles of exosomes in Parkinson's disease: an overview. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 469-476.	1.1	43
465	Clinical implications of extracellular vesicles in neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 813-824.	1.5	14
466	In Vitro Modification of Bacterial Cyanophycin and Cyanophycin Dipeptides Using Chemical Agents Towards Novel Variants of the Biopolymer. <i>Earth Systems and Environment</i> , 2019, 3, 637-650.	3.0	6
467	Development and Cell Biology of the Blood-Brain Barrier. <i>Annual Review of Cell and Developmental Biology</i> , 2019, 35, 591-613.	4.0	251

#	ARTICLE	IF	CITATIONS
468	Pharmacokinetics of Systemic Drug Delivery. , 2019, , 39-56.		0
469	Developmental exposure to BDE-99 hinders cerebrovascular growth and disturbs vascular barrier formation in zebrafish larvae. <i>Aquatic Toxicology</i> , 2019, 214, 105224.	1.9	13
470	Localized Blood–Brain Barrier Opening in Ovine Model Using Image-Guided Transcranial Focused Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2391-2404.	0.7	20
471	Novel Target Selection for Nuclear Medicine Studies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 357-368.	2.5	12
472	L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs). <i>International Journal of Pharmaceutics</i> , 2019, 571, 118714.	2.6	23
473	An advanced focused ultrasound protocol improves the blood-brain barrier permeability and doxorubicin delivery into the rat brain. <i>Journal of Controlled Release</i> , 2019, 315, 55-64.	4.8	16
474	Hybrid elastomer–plastic microfluidic device as a convenient model for mimicking the blood–brain barrier in vitro. <i>Biomedical Microdevices</i> , 2019, 21, 90.	1.4	12
475	Nasal route for vaccine and drug delivery: Features and current opportunities. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118813.	2.6	84
476	Cardiac Surgery and the Blood-Brain Barrier. <i>Anesthesiology Clinics</i> , 2019, 37, 787-800.	0.6	4
477	Computational Nanoscopy of Tight Junctions at the Blood–Brain Barrier Interface. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5583.	1.8	18
478	Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study. <i>Journal of Veterinary Internal Medicine</i> , 2019, 33, 2709-2717.	0.6	18
479	Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. <i>Nature Communications</i> , 2019, 10, 3850.	5.8	199
480	In Vitro Blood–Brain Barrier Models for Nanomedicine: Particle-Specific Effects and Methodological Drawbacks. <i>ACS Applied Bio Materials</i> , 2019, 2, 3279-3289.	2.3	7
481	L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia. <i>Scientific Reports</i> , 2019, 9, 12860.	1.6	53
482	Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan. <i>Marine Drugs</i> , 2019, 17, 525.	2.2	18
483	Jiadifenolide induces the expression of cellular communication network factor (CCN) genes, and CCN2 exhibits neurotrophic activity in neuronal precursor cells derived from human induced pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 309-315.	1.0	8
484	Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons. <i>ACS Nano</i> , 2019, 13, 10961-10971.	7.3	15
485	Nanoformulations for glioblastoma multiforme: a new hope for treatment. <i>Future Medicinal Chemistry</i> , 2019, 11, 2461-2482.	1.1	21

#	ARTICLE	IF	CITATIONS
486	Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents. <i>Progress in Neurobiology</i> , 2019, 183, 101694.	2.8	127
487	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 991-996.	1.3	19
488	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <i>Antibodies</i> , 2019, 8, 3.	1.2	22
489	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019, 104, 1812-1821.	1.7	32
490	The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2019, 21, 12-24.	1.8	37
491	Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies. <i>Inorganic Chemistry</i> , 2019, 58, 13509-13527.	1.9	61
492	Therapeutic Potential of Intranasal Drug Delivery in Preclinical Studies of Ischemic Stroke and Intracerebral Hemorrhage. <i>Springer Series in Translational Stroke Research</i> , 2019, , 27-42.	0.1	3
493	Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions. <i>Theranostics</i> , 2019, 9, 3754-3767.	4.6	82
494	Tumor-derived extracellular vesicles in breast cancer: From bench to bedside. <i>Cancer Letters</i> , 2019, 460, 54-64.	3.2	48
495	Advancements in Canadian Biomaterials Research in Neurotraumatic Diagnosis and Therapies. <i>Processes</i> , 2019, 7, 336.	1.3	2
496	Behavioural effects of inhalation exposure to dizocilpine (MK-801) in mice. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109038.	2.5	7
497	Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1147, 65-91.	0.8	22
498	Therapeutic Intranasal Delivery for Stroke and Neurological Disorders. <i>Springer Series in Translational Stroke Research</i> , 2019, , .	0.1	3
499	The Effects of Various Essential Oils on Epilepsy and Acute Seizure: A Systematic Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-14.	0.5	44
500	Targeting Strategies. , 2019, , 195-263.		1
501	Intranasal Delivery of Therapeutic Peptides for Treatment of Ischemic Brain Injury. <i>Springer Series in Translational Stroke Research</i> , 2019, , 65-73.	0.1	3
504	The need for mathematical modelling of spatial drug distribution within the brain. <i>Fluids and Barriers of the CNS</i> , 2019, 16, 12.	2.4	60
505	Expanding the MiniApâ€4 BBBâ€5shuttle family: Evaluation of proline <i>cis</i>/<i>trans</i> ratio as tool to fineâ€tune transport. <i>Journal of Peptide Science</i> , 2019, 25, e3172.	0.8	5

#	ARTICLE	IF	CITATIONS
506	Interleukin-4 signalling pathway underlies the anxiolytic effect induced by 3-deoxyadenosine. <i>Psychopharmacology</i> , 2019, 236, 2959-2973.	1.5	7
507	Metastatic brain tumor models and drug brain penetration analysis. , 2019, , 197-232.		0
508	Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice. <i>European Neuropsychopharmacology</i> , 2019, 29, S565-S566.	0.3	0
509	A MALDI-TOF-based Method for Studying the Transport of BBB Shuttlesâ€”Enhancing Sensitivity and Versatility of Cell-Based In Vitro Transport Models. <i>Scientific Reports</i> , 2019, 9, 4875.	1.6	5
510	Brain Metastases from Lung Cancer: Is MET an Actionable Target?. <i>Cancers</i> , 2019, 11, 271.	1.7	12
511	Imaging Hyperpolarized Pyruvate and Lactate after Bloodâ€”Brain Barrier Disruption with Focused Ultrasound. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2591-2601.	1.7	10
512	Brain-Targeted Drug Delivery with Surface-Modified Nanoparticles. , 2019, , 277-310.		5
513	The Hypotonic Environmental Changes Affect Liposomal Formulations for Nose-to-Brain Targeted Drug Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2570-2579.	1.6	10
514	Nanodelivery of therapeutic agents in Parkinson's disease. <i>Progress in Brain Research</i> , 2019, 245, 263-279.	0.9	8
515	Exosome nanocarriers. , 2019, , 189-218.		2
516	Tumor Targeting by Peptide-Decorated Gold Nanoparticles. <i>Molecular Pharmaceutics</i> , 2019, 16, 2430-2444.	2.3	37
517	MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain. <i>Methods in Molecular Biology</i> , 2019, 1950, 177-197.	0.4	36
518	Involvement of GABAA receptor gamma 2 subunit in the anxiety-like behaviour and cognitive dysfunction in pentylenetetrazole-kindled rats. <i>European Neuropsychopharmacology</i> , 2019, 29, S566-S567.	0.3	0
519	Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimerâ€™s disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 337-348.	0.7	28
520	Intrathecal Delivery of Folate Conjugated near-Infrared Quantum Dots for Targeted in Vivo Imaging of Gliomas in Mice Brains. <i>ACS Applied Bio Materials</i> , 2019, 2, 1432-1439.	2.3	10
521	Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. <i>Communications Biology</i> , 2019, 2, 76.	2.0	103
522	Adeno-Associated Virus Vectors. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	2
523	Pharmaceutical Considerations for Treatment of the Central Nervous System. , 2019, , 859-863.		0

#	ARTICLE	IF	CITATIONS
524	Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model. <i>Scientific Reports</i> , 2019, 9, 19402.	1.6	37
525	The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention. <i>Future Medicinal Chemistry</i> , 2019, 11, 1853-1857.	1.1	7
526	Empirical and Theoretical Characterization of the Diffusion Process of Different Gadolinium-Based Nanoparticles within the Brain Tissue after Ultrasound-Induced Permeabilization of the Blood-Brain Barrier. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-13.	0.4	21
527	Characterization of a Fiber Bundle-Based Real-Time Ultrasound/Photoacoustic Imaging System and Its In Vivo Functional Imaging Applications. <i>Micromachines</i> , 2019, 10, 820.	1.4	13
528	Astrocyte-Targeted Transporter-Utilizing Derivatives of Ferulic Acid Can Have Multifunctional Effects Ameliorating Inflammation and Oxidative Stress in the Brain. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	1.9	17
529	Neurovascular unit transport responses to ischemia and common coexisting conditions: smoking and diabetes. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 316, C2-C15.	2.1	19
530	A microfluidic model of human brain (1/4HuB) for assessment of blood brain barrier. <i>Bioengineering and Translational Medicine</i> , 2019, 4, e10126.	3.9	76
531	Pharmacokinetics and brain distribution of amitraz and its metabolites in rats. <i>Environmental Toxicology and Pharmacology</i> , 2019, 65, 40-45.	2.0	5
532	Methods to Quantify Nanomaterial Association with, and Distribution Across, the Blood-Brain Barrier In Vivo. <i>Methods in Molecular Biology</i> , 2019, 1894, 281-299.	0.4	1
533	Exosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy. <i>Acta Biomaterialia</i> , 2019, 86, 1-14.	4.1	275
534	Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 480-496.	4.3	117
535	Chemical structure modifications and nanotechnology applications for improving ADME-Tox properties, a review. <i>Archiv Der Pharmazie</i> , 2019, 352, e1800213.	2.1	10
536	In further defense of nonclinical abuse liability testing of biologics. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 101, 103-120.	1.3	1
537	Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1104, 29-39.	1.2	26
538	Carrier-mediated transportation through BBB. , 2019, , 129-158.		10
539	Evaluating the safety profile of focused ultrasound and microbubble-mediated treatments to increase blood-brain barrier permeability. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 129-142.	2.4	54
540	Blood-Brain Barrier: From Physiology to Disease and Back. <i>Physiological Reviews</i> , 2019, 99, 21-78.	13.1	1,232
541	Recent progress in blood-brain barrier transportation research. , 2019, , 33-51.		12

#	ARTICLE	IF	CITATIONS
542	The intra-brain distribution of brain targeting delivery systems. , 2019, , 409-438.		7
543	In vitro and in vivo models of BBB to evaluate brain targeting drug delivery. , 2019, , 53-101.		17
544	Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. <i>Biomaterials</i> , 2019, 190-191, 38-50.	5.7	87
545	Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's $\beta$ -amyloid self-assembly. <i>Biomaterials</i> , 2019, 190-191, 121-132.	5.7	62
546	Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior. <i>Biomaterials</i> , 2019, 190-191, 24-37.	5.7	141
547	Vectorizing agrochemicals: enhancing bioavailability via carrier-mediated transport. <i>Pest Management Science</i> , 2019, 75, 1507-1516.	1.7	37
548	Nanotoxicity. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	5
549	Evaluation of blood-brain barrier penetration and examination of binding to human serum albumin of 7-O-arylpiperazinylicoumarins as potential antipsychotic agents. <i>Bioorganic Chemistry</i> , 2019, 84, 211-225.	2.0	10
550	Porous Silicon Nanoparticles for Applications in Nano-medicine. , 2019, , 211-226.		1
551	Insights into major facilitator superfamily domain-containing protein $\alpha$ 2 (Mfsd2a) in physiology and pathophysiology. What do we know so far?. <i>Journal of Neuroscience Research</i> , 2020, 98, 29-41.	1.3	32
552	Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 901-917.	2.0	12
553	Blood-brain barrier regulation in psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 726, 133664.	1.0	178
554	BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine. <i>Neuropharmacology</i> , 2020, 166, 107678.	2.0	13
555	The Rise of Molecules Able To Regenerate the Central Nervous System. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 490-511.	2.9	7
556	Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 443-458.	2.1	50
557	Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. <i>Drug Delivery and Translational Research</i> , 2020, 10, 304-318.	3.0	101
558	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. <i>Annals of Neurology</i> , 2020, 87, 30-39.	2.8	64
559	Influence of transporters in treating cancers in the CNS. , 2020, , 277-301.		2

#	ARTICLE	IF	CITATIONS
560	Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood–Brain Barrier of Human Brain and Glioblastoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1116-1127.	2.3	46
561	The potential of exosomes as theragnostics in various clinical situations. , 2020, , 467-486.		11
562	Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 3.	1.0	13
563	A 2D HPLC-MS/MS method for several antibiotics in blood plasma, plasma water, and diverse tissue samples. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 715-725.	1.9	19
564	Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. <i>Xenobiotica</i> , 2020, 50, 1101-1114.	0.5	3
565	Microphysiological systems for recapitulating physiology and function of blood-brain barrier. <i>Biomaterials</i> , 2020, 232, 119732.	5.7	34
566	The fluorescent dye 3,3'-diethylthiatricarbocyanine iodide is unsuitable for in vivo imaging of myelination in the mouse. <i>Brain Research Bulletin</i> , 2020, 156, 10-14.	1.4	1
567	Recent Advances in the Design of Self-Delivery Amphiphilic Drugs and Vaccines. <i>Advanced Therapeutics</i> , 2020, 3, 1900107.	1.6	3
568	Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth. <i>Journal of Drug Targeting</i> , 2020, 28, 617-626.	2.1	32
569	Nanocarrier-based drug combination therapy for glioblastoma. <i>Theranostics</i> , 2020, 10, 1355-1372.	4.6	203
570	The solute carrier transporters and the brain: Physiological and pharmacological implications. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 131-144.	4.3	92
571	The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. <i>Nature Reviews Cancer</i> , 2020, 20, 26-41.	12.8	908
572	The blood-brain barrier: Physiology and strategies for drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 165-166, 1-14.	6.6	292
573	Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. <i>Peptides</i> , 2020, 125, 170225.	1.2	30
574	Docosahexaenoic Acid-Loaded Polylactic Acid Core-Shell Nanofiber Membranes for Regenerative Medicine after Spinal Cord Injury: In Vitro and In Vivo Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7031.	1.8	6
575	&lt;p>&gt;Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications&lt;/p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 6917-6934.	3.3	564
576	Blood-brain-barrier penetrable thiolated paclitaxel-oligo (p-phenylene vinylene) nanomedicine with increased drug efficiency for glioblastoma treatment. <i>Nano Today</i> , 2020, 35, 100969.	6.2	20
577	In vivo delivery of a fluorescent FPR2/ALX-targeted probe using focused ultrasound and microbubbles to image activated microglia. <i>RSC Chemical Biology</i> , 2020, 1, 385-389.	2.0	3



#	ARTICLE	IF	CITATIONS
578	Designing peptide nanoparticles for efficient brain delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 52-77.	6.6	33
579	Role for caveolin-mediated transcytosis in facilitating transport of large cargoes into the brain via ultrasound. <i>Journal of Controlled Release</i> , 2020, 327, 667-675.	4.8	41
580	Caveolae-mediated transport at the injured blood-brain barrier as an underexplored pathway for central nervous system drug delivery. <i>Current Opinion in Chemical Engineering</i> , 2020, 30, 86-95.	3.8	9
581	The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. <i>International Journal of Pharmaceutics</i> , 2020, 589, 119832.	2.6	27
582	Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation. <i>Advances in Colloid and Interface Science</i> , 2020, 277, 102121.	7.0	25
583	Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease. <i>Frontiers in Neuroendocrinology</i> , 2020, 59, 100857.	2.5	50
584	Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours. <i>IET Nanobiotechnology</i> , 2020, 14, 441-448.	1.9	16
585	Intact or in Pieces? A Look at How Clinically Approved, Biodegradable Block Co-Polymers Affect Blood Components. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 4846-4850.	2.6	14
586	Functions of Endothelial Cilia in the Regulation of Vascular Barriers. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 626.	1.8	20
587	Focused Ultrasound for Noninvasive, Focal Pharmacologic Neurointervention. <i>Frontiers in Neuroscience</i> , 2020, 14, 675.	1.4	25
588	Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5271.	1.8	67
589	Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival. <i>Molecular Neurobiology</i> , 2020, 57, 4563-4577.	1.9	15
590	The Paradox of HIV Blood-Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies. <i>Trends in Neurosciences</i> , 2020, 43, 695-708.	4.2	85
591	Hydroxysafflor Yellow A Together with Blood-Brain Barrier Regulator Lexiscan for Cerebral Ischemia Reperfusion Injury Treatment. <i>ACS Omega</i> , 2020, 5, 19151-19164.	1.6	12
592	Mannosylated glycoliposomes for the delivery of a peptide kappa opioid receptor antagonist to the brain. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 290-296.	2.0	16
593	Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting $\mu$ -opioid receptor antagonists. <i>Regional Anesthesia and Pain Medicine</i> , 2020, 45, 688-695.	1.1	18
594	Fluorescent artificial receptor-based membrane assay (FARMA) for spatiotemporally resolved monitoring of biomembrane permeability. <i>Communications Biology</i> , 2020, 3, 383.	2.0	32
595	Neutrophils Enable Local and Non-Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart. <i>Advanced Materials</i> , 2020, 32, e2003598.	11.1	66

#	ARTICLE	IF	CITATIONS
596	Liposomes Decorated with 2-(4-aminophenyl)benzothiazole Effectively Inhibit A $\beta$ Fibril Formation and Exhibit In Vitro Brain-Targeting Potential. <i>Biomacromolecules</i> , 2020, 21, 4685-4698.	2.6	10
597	iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. <i>Polymers</i> , 2020, 12, 1906.	2.0	45
598	Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models. <i>Acta Neuropathologica Communications</i> , 2020, 8, 126.	2.4	5
599	Site-specific opening of the blood-brain barrier by extracellular histones. <i>Journal of Neuroinflammation</i> , 2020, 17, 281.	3.1	19
600	Nanocarriers for effective nutraceutical delivery to the brain. <i>Neurochemistry International</i> , 2020, 140, 104851.	1.9	15
601	Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio. <i>Pharmaceutical Research</i> , 2020, 37, 175.	1.7	7
602	Probing the interaction between EC1-EC2 domain of E-cadherin with conformational structure of cyclic ADTC7 (Ac-CDTPDC-NH <sub>2</sub> ) peptide using molecular docking approach. <i>Journal of Physics: Conference Series</i> , 2020, 1524, 012081.	0.3	4
603	Heat Shock Proteins, a Key Modulator of Neuroinflammation in Alzheimer's Disease. <i>Heat Shock Proteins</i> , 2020, , 89-145.	0.2	1
604	RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. <i>Molecular Pharmaceutics</i> , 2020, 17, 4040-4066.	2.3	22
605	Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery. <i>Molecules</i> , 2020, 25, 4016.	1.7	9
606	Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme. <i>Pharmaceutics</i> , 2020, 12, 860.	2.0	30
607	Effect of Nanoparticle Composition, Size, Shape, and Stiffness on Penetration Across the Blood-Brain Barrier. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 4916-4928.	2.6	90
608	High Mobility Group Box-1 and Blood-Brain Barrier Disruption. <i>Cells</i> , 2020, 9, 2650.	1.8	65
609	Stem Cell-Derived Exosomes as Therapeutic Approach for Neurodegenerative Disorders: From Biology to Biotechnology. <i>Cells</i> , 2020, 9, 2663.	1.8	26
610	The New Frontiers in Neurodegenerative Diseases Treatment: Liposomal-Based Strategies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 566767.	2.0	18
611	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. <i>Clinical Cancer Research</i> , 2020, 26, 4186-4197.	3.2	44
612	Peptide based drug delivery systems to the brain. <i>Nano Express</i> , 2020, 1, 012002.	1.2	22
613	Effects of Drugs of Abuse on the Blood-Brain Barrier: A Brief Overview. <i>Frontiers in Neuroscience</i> , 2020, 14, 513.	1.4	73

#	ARTICLE	IF	CITATIONS
614	Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows. <i>Cells</i> , 2020, 9, 1074.	1.8	32
615	Nanostructured Lipid Carriers to Mediate Brain Delivery of Temazepam: Design and In Vivo Study. <i>Pharmaceutics</i> , 2020, 12, 451.	2.0	44
616	Clinical Applications of Extracellular Vesicles in the Diagnosis and Treatment of Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2020, 37, 2045-2056.	1.7	25
617	Phospholipase A <sub>2</sub> Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain. <i>ACS Nano</i> , 2020, 14, 8103-8115.	7.3	16
618	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. <i>Nanomedicine</i> , 2020, 15, 1239-1261.	1.7	68
619	Therapeutic Nanoparticles and Their Targeted Delivery Applications. <i>Molecules</i> , 2020, 25, 2193.	1.7	413
620	Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme. <i>Journal of Controlled Release</i> , 2020, 324, 181-193.	4.8	14
621	Neuroprotection by curcumin: A review on brain delivery strategies. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119476.	2.6	48
622	The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier. <i>Frontiers in Physiology</i> , 2020, 11, 398.	1.3	31
623	Emerging New Concepts of Degradable Technologies. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 464-474.	4.0	116
624	Heterogeneity and vascular permeability of breast cancer brain metastases. <i>Cancer Letters</i> , 2020, 489, 174-181.	3.2	15
625	Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs. <i>Pathogens</i> , 2020, 9, 405.	1.2	35
626	Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. <i>Frontiers in Neuroscience</i> , 2020, 14, 494.	1.4	156
627	Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 739.	1.3	113
628	Engineering the drug carrier biointerface to overcome biological barriers to drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 89-108.	6.6	91
629	Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1140-1152.	1.1	13
631	In vitro modeling of the neurovascular unit: advances in the field. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 22.	2.4	105
632	Sonoselective transfection of cerebral vasculature without blood-brain barrier disruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5644-5654.	3.3	41

#	ARTICLE	IF	CITATIONS
633	Potential Roles of Exosomes in Parkinson's Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 86.	1.8	84
634	Unprecedented Potential for Neural Drug Discovery Based on Self-Organizing hiPSC Platforms. <i>Molecules</i> , 2020, 25, 1150.	1.7	7
635	Biological barriers, and the influence of protein binding on the passage of drugs across them. <i>Molecular Biology Reports</i> , 2020, 47, 3221-3231.	1.0	84
636	Glutamine transporters as pharmacological targets: From function to drug design. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 207-219.	4.3	26
637	Development of an Integrated Tissue Pretreatment Protocol for Enhanced MALDI MS Imaging of Drug Distribution in the Brain. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1066-1073.	1.2	14
638	Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions. <i>Journal of Pain Research</i> , 2020, Volume 13, 447-456.	0.8	3
639	CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 302.	1.3	13
640	Metabolite Profiling and Distribution of Militarine in Rats Using UPLC-Q-TOF-MS/MS. <i>Molecules</i> , 2020, 25, 1082.	1.7	11
641	Breaking Barriers: Bioinspired Strategies for Targeted Neuronal Delivery to the Central Nervous System. <i>Pharmaceutics</i> , 2020, 12, 192.	2.0	16
642	Effect of Lonicerae japonicae Flos Carbonisata-Derived Carbon Dots on Rat Models of Fever and Hypothermia Induced by Lipopolysaccharide. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 4139-4149.	3.3	26
643	The Blood-Cerebrospinal Fluid Barrier Is Selective for Red Cabbage Anthocyanins and Their Metabolites. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 8274-8285.	2.4	6
644	Use of exosomes as vectors to carry advanced therapies. <i>RSC Advances</i> , 2020, 10, 23975-23987.	1.7	21
645	Pulse Pressure: An Emerging Therapeutic Target for Dementia. <i>Frontiers in Neuroscience</i> , 2020, 14, 669.	1.4	32
646	Preclinical Evaluation of Acylhydrazone SB-AF-1002 as a Novel Broad-Spectrum Antifungal Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
647	Potential nanocarriers for the delivery of drugs to the brain. , 2020, , 449-472.		0
648	A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. <i>Annals of Oncology</i> , 2020, 31, 1397-1404.	0.6	98
649	Intranasal delivery of gabapentin loaded optimized nanoemulsion for augmented permeation. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 56, 101606.	1.4	14
650	Active matter therapeutics. <i>Nano Today</i> , 2020, 31, 100836.	6.2	54

#	ARTICLE	IF	CITATIONS
651	Functionalized Lipopeptide Micelles as Highly Efficient NMR Depolarization Seed Points for Targeted Cell Labelling in Xenon MRI. <i>Advanced Biology</i> , 2020, 4, 1900251.	3.0	9
652	Peripheral-to-central immune communication at the area postrema glial-barrier following bleomycin-induced sterile lung injury in adult rats. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 610-633.	2.0	14
653	Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn. <i>Scientific Reports</i> , 2020, 10, 3685.	1.6	38
654	Anticonvulsant Activity of Essential Oil From Leaves of <i>Zhumeria majdae</i> (Rech.) in Mice: The Role of GABA A Neurotransmission and the Nitric Oxide Pathway. <i>Clinical and Translational Science</i> , 2020, 13, 785-797.	1.5	2
655	Recent advances in neurogenic and neuroprotective effects of curcumin through the induction of neural stem cells. <i>Biotechnology and Applied Biochemistry</i> , 2020, 67, 430-441.	1.4	15
656	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 796-805.	2.3	14
657	Persistent prolate polymersomes for enhanced co-delivery of hydrophilic and hydrophobic drugs. <i>Nanotechnology</i> , 2020, 31, 175103.	1.3	8
658	Biological evaluation and pharmacokinetic profiling of a coumarin-benzothiazole hybrid as a new scaffold for human gliomas. <i>Medicine in Drug Discovery</i> , 2020, 7, 100012.	2.3	3
659	Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?. <i>Pharmaceutics</i> , 2020, 12, 62.	2.0	30
660	Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. <i>Brain Research Bulletin</i> , 2020, 160, 65-73.	1.4	27
661	&lt;p&gt;Overcoming the Blood&quot;Brain Barrier: Successes and Challenges in&quot;Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 2999-3022.	3.3	61
662	Intramuscular antagonism of the G-protein coupled estrogen receptor 1 partially affects dimorphic characteristics of the syrinx, but is ineffective within the neural song circuit of zebra finches. <i>General and Comparative Endocrinology</i> , 2020, 293, 113492.	0.8	0
663	Amphetamine decorated cationic lipid nanoparticles cross the blood&quot;brain barrier: therapeutic promise for combating glioblastoma. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4318-4330.	2.9	33
664	Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. <i>Molecules</i> , 2020, 25, 1929.	1.7	94
665	Evaluation of Cell&quot;Penetrating Peptides Using Microfluidic In Vitro 3D Brain Endothelial Barrier. <i>Macromolecular Bioscience</i> , 2020, 20, 1900425.	2.1	4
666	Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. <i>Brain Research Bulletin</i> , 2020, 160, 121-140.	1.4	72
667	<i>In Vitro</i> Blood&quot;Brain Barrier Permeability and Cytotoxicity of an Atorvastatin-Loaded Nanoformulation Against Glioblastoma in 2D and 3D Models. <i>Molecular Pharmaceutics</i> , 2020, 17, 1835-1847.	2.3	25
668	LRP-1 Mediated Endocytosis of EFE Across the Blood&quot;Brain Barrier; Protein&quot;Protein Interaction and Molecular Dynamics Analysis. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 71-81.	0.9	3

#	ARTICLE	IF	CITATIONS
669	Treatable Cause of Pancytopenia, Recurrent Infections and Refractory Epilepsy: Secondary to Hereditary Folate Malabsorption (HFM) Due to Novel Pathogenic Variant. <i>Indian Journal of Pediatrics</i> , 2021, 88, 586-588.	0.3	1
670	Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies. <i>Biomaterials</i> , 2021, 269, 120461.	5.7	10
671	From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier. <i>Advanced Therapeutics</i> , 2021, 4, 2000092.	1.6	70
672	The future of cerebral organoids in drug discovery. <i>Seminars in Cell and Developmental Biology</i> , 2021, 111, 67-73.	2.3	15
673	Current approaches and prospective drug targeting to brain. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 61, 102098.	1.4	11
674	A combined spectroscopic and molecular dynamic analysis of the inclusion behaviour of L-serine and $\beta$ -cyclodextrin. <i>Journal of Molecular Liquids</i> , 2021, 321, 114447.	2.3	11
675	Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine. <i>International Journal of Biological Macromolecules</i> , 2021, 167, 1527-1543.	3.6	31
676	Nanotherapy for Brain Tumor Drug Delivery. <i>NeuroMethods</i> , 2021, , .	0.2	2
677	Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme. <i>Drug Research</i> , 2021, 71, 122-137.	0.7	15
678	Basic physiology of the blood-brain barrier in health and disease: a brief overview. <i>Tissue Barriers</i> , 2021, 9, 1840913.	1.6	27
679	T Cell-Mediated Transport of Polymer Nanoparticles across the Blood-Brain Barrier. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001375.	3.9	36
680	Brain metastasis models: What should we aim to achieve better treatments?. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 79-99.	6.6	13
681	Delivery of acetaminophen to the central nervous system and the pharmacological effect after intranasal administration with a mucoadhesive agent and absorption enhancer. <i>International Journal of Pharmaceutics</i> , 2021, 594, 120046.	2.6	1
682	Reduced pericyte and tight junction coverage in old diabetic rats are associated with hyperglycemia-induced cerebrovascular pericyte dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H549-H562.	1.5	35
683	Imaging as a tool to accelerate the translation of extracellular vesicle-based therapies for central nervous system diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1688.	3.3	4
684	Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. <i>Journal of Controlled Release</i> , 2021, 330, 641-657.	4.8	74
685	Neuropathology of Drug Abuse. , 2021, , .		1
686	Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 1-20.	1.9	72

#	ARTICLE	IF	CITATIONS
687	A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 297-315.	1.8	7
688	A review on synthesis and applications of dendrimers. <i>Journal of the Iranian Chemical Society</i> , 2021, 18, 503-517.	1.2	35
689	Applications of direct nose-to-brain drug delivery in biomedicine, biotechnology, tissue engineering, and immunology. , 2021, , 267-285.		0
690	Functionalized biopolymer-based drug delivery systems: current status and future perspectives. , 2021, , 723-746.		0
691	Nanoparticles beyond the blood-brain barrier for glioblastoma. , 2021, , 707-747.		0
692	Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles. , 2021, 12, 1476.		12
693	PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. <i>Progress in Medicinal Chemistry</i> , 2021, 60, 67-190.	4.1	23
694	A novel cyclic peptide (Naturido) modulates glia-neuron interactions in vitro and reverses ageing-related deficits in senescence-accelerated mice. <i>PLoS ONE</i> , 2021, 16, e0245235.	1.1	6
695	Central Nervous System Bioavailability. , 2021, , 1-10.		0
696	Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances $\beta$ 2-amyloid phagocytosis. <i>Nanoscale</i> , 2021, 13, 939-952.	2.8	20
697	Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab066.	0.4	10
698	Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1695.	3.3	90
699	Intranasal delivery of phenytoin-loaded nanoparticles to the brain suppresses pentylenetetrazol-induced generalized tonic clonic seizures in an epilepsy mouse model. <i>Biomaterials Science</i> , 2021, 9, 7547-7564.	2.6	11
700	The 4-(Phenylsulfanyl) butan-2-one Improves Impaired Fear Memory Retrieval and Reduces Excessive Inflammatory Response in Triple Transgenic Alzheimer's Disease Mice. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 615079.	1.7	10
701	New Idea for Narrowing an Energy Gap by Selective Perturbation of One Frontier Molecular Orbital. <i>Chemistry Letters</i> , 2021, 50, 269-279.	0.7	24
702	Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression. <i>Current Drug Targets</i> , 2021, 22, 183-191.	1.0	8
703	The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. <i>Supportive Care in Cancer</i> , 2021, 29, 5209-5218.	1.0	3
704	Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!. <i>European Journal of Pharmacology</i> , 2021, 894, 173851.	1.7	17

#	ARTICLE	IF	CITATIONS
705	Can Natural Products Exert Neuroprotection without Crossing the Blood–Brain Barrier?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3356.	1.8	22
706	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 656921.	1.4	16
707	Overcoming Mfsd2a–Mediated Low Transcytosis to Boost Nanoparticle Delivery to Brain for Chemotherapy of Brain Metastases. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001997.	3.9	28
708	First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines. <i>BMC Veterinary Research</i> , 2021, 17, 103.	0.7	16
709	Treating viruses in the brain: Perspectives from NeuroAIDS. <i>Neuroscience Letters</i> , 2021, 748, 135691.	1.0	7
710	Therapeutic Agent Delivery Across the Blood–Brain Barrier Using Focused Ultrasound. <i>Annual Review of Biomedical Engineering</i> , 2021, 23, 89-113.	5.7	34
711	The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 629832.	2.0	27
712	Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 357-381.	1.3	15
713	Healthy aging and the blood–brain barrier. <i>Nature Aging</i> , 2021, 1, 243-254.	5.3	116
714	Intriguing Biomedical Applications of Synthetic and Natural Cell-Derived Vesicles: A Comparative Overview. <i>ACS Applied Bio Materials</i> , 2021, 4, 2863-2885.	2.3	15
715	Docking and molecular dynamic study of isoniazid derivatives as anti-tuberculosis drug candidate. <i>Chemical Data Collections</i> , 2021, 32, 100647.	1.1	10
716	Lipid nanoparticles for the transport of drugs like dopamine through the blood-brain barrier. <i>Journal of Nanoparticle Research</i> , 2021, 23, 1.	0.8	8
717	Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance. <i>Molecules</i> , 2021, 26, 2047.	1.7	81
718	Therapeutic Delivery to Central Nervous System. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 291-303.	0.8	10
719	Evolving new-age strategies to transport therapeutics across the blood-brain-barrier. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120351.	2.6	29
720	Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts. <i>Cancer Gene Therapy</i> , 2022, 29, 533-542.	2.2	5
721	Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment. <i>Molecules</i> , 2021, 26, 2262.	1.7	9
723	Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3742.	1.8	21



#	ARTICLE	IF	CITATIONS
724	Modulation of Blood–Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment. <i>Biomolecules</i> , 2021, 11, 633.	1.8	10
725	Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. <i>Pharmaceutics</i> , 2021, 13, 581.	2.0	20
726	Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer’s Disease Pathology and Improve Cognitive Deficits. <i>Biomedicines</i> , 2021, 9, 594.	1.4	55
727	Focused Ultrasound and Microbubble Treatment Increases Delivery of Transferrin Receptor-Targeting Liposomes to the Brain. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 1343-1355.	0.7	23
728	Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives. <i>Molecular Pharmaceutics</i> , 2021, 18, 2142-2160.	2.3	31
729	Overcoming delivery barriers in immunotherapy for glioblastoma. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2302-2316.	3.0	13
730	Immunotherapy for Glioblastoma: Current Progress and Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 676301.	2.2	83
731	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer’s Disease. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4305.	1.3	26
732	Cubosomes enhance drug permeability across the blood–brain barrier in zebrafish. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120411.	2.6	22
733	Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 2106-2149.	2.6	95
734	Emerging Application of Nanorobotics and Artificial Intelligence To Cross the BBB: Advances in Design, Controlled Maneuvering, and Targeting of the Barriers. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1835-1853.	1.7	66
735	Extracellular Vesicle Application as a Novel Therapeutic Strategy for Ischemic Stroke. <i>Translational Stroke Research</i> , 2022, 13, 171-187.	2.3	9
736	<i>In Vitro</i> and <i>In Vivo</i> Activities, Absorption, Tissue Distribution, and Excretion of OBP-4, a Potential Anti-Clostridioides difficile Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	0
738	Targeted Drug Delivery: Trends and Perspectives. <i>Current Drug Delivery</i> , 2021, 18, 1435-1455.	0.8	38
739	Blood-Brain Barrier Dysfunction in the Detrimental Brain Function. , 0, , .		5
740	Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. <i>Frontiers in Immunology</i> , 2021, 12, 634031.	2.2	2
741	Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives. <i>Nanomaterials</i> , 2021, 11, 1481.	1.9	74
742	Endothelial-specific insulin receptor substrate-1 overexpression worsens neonatal hypoxic-ischemic brain injury via mTOR-mediated tight junction disassembly. <i>Cell Death Discovery</i> , 2021, 7, 150.	2.0	7

#	ARTICLE	IF	CITATIONS
743	A narrative review of research progress on drug therapies for glioblastoma multiforme. <i>Annals of Translational Medicine</i> , 2021, 9, 943-943.	0.7	11
744	Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. <i>Nature Communications</i> , 2021, 12, 4121.	5.8	58
745	PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2021, 13, 1042.	2.0	39
746	Probing Cerebral Metabolism with Hyperpolarized <sup>13</sup> C Imaging after Opening the Blood–Brain Barrier with Focused Ultrasound. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2820-2828.	1.7	4
747	On the therapeutic targets and pharmacological treatments for pain relief following spinal cord injury: A mechanistic review. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111563.	2.5	17
748	Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments. <i>Frontiers in Immunology</i> , 2021, 12, 716407.	2.2	40
749	NOSE TO BRAIN DELIVERY: ROLE OF VIRAL AND NON-VIRAL VECTORS FOR NEUROLOGICAL DISORDER. <i>Indian Drugs</i> , 2021, 58, 7-20.	0.1	0
750	Transportation of Single-Domain Antibodies through the Blood–Brain Barrier. <i>Biomolecules</i> , 2021, 11, 1131.	1.8	35
751	Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7996.	1.8	4
752	Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. <i>Pharmaceutics</i> , 2021, 13, 1183.	2.0	81
753	Novel brain-targeting 3-n-butylphthalide prodrugs for ischemic stroke treatment. <i>Journal of Controlled Release</i> , 2021, 335, 498-514.	4.8	17
754	Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration. <i>Pharmaceutics</i> , 2021, 13, 1144.	2.0	13
755	B3Pdb: an archive of blood–brain barrier-penetrating peptides. <i>Brain Structure and Function</i> , 2021, 226, 2489-2495.	1.2	14
756	Extracellular vesicles for the treatment of central nervous system diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 535-552.	6.6	39
757	The Effect of Plasma Protein Binding on the Therapeutic Monitoring of Antiseizure Medications. <i>Pharmaceutics</i> , 2021, 13, 1208.	2.0	21
758	Cerebrospinal fluid in forensic toxicology: Current status and future perspectives. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2021, 82, 102231.	0.5	4
759	Phytochemical and Over-The-Counter Drug Interactions: Involvement of Phase I and II Drug-Metabolizing Enzymes and Phase III Transporters. <i>Journal of Medicinal Food</i> , 2021, 24, 786-805.	0.8	6
760	Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2306-2325.	5.7	134

#	ARTICLE	IF	CITATIONS
761	Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. <i>Frontiers in Medical Technology</i> , 2021, 3, 678593.	1.3	11
762	Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. <i>Cells</i> , 2021, 10, 2032.	1.8	12
763	Dynamic nanoassemblies for imaging and therapy of neurological disorders. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113832.	6.6	15
764	Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1100-1125.	5.7	20
765	An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111906.	2.5	32
766	Filamentous Bacteriophage "A Powerful Carrier for Glioma Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 729336.	2.2	12
767	Neurosteroids: Structure-Uptake Relationships and Computational Modeling of Organic Anion Transporting Polypeptides (OATP)1A2. <i>Molecules</i> , 2021, 26, 5662.	1.7	6
768	Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. <i>Pharmaceutics</i> , 2021, 13, 1479.	2.0	5
769	Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies. <i>Journal of Hazardous Materials</i> , 2022, 424, 127386.	6.5	6
770	Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1. <i>Scientific Reports</i> , 2021, 11, 17471.	1.6	4
771	Acoustic Cluster Therapy (ACT <sup>®</sup> ) enhances accumulation of polymeric micelles in the murine brain. <i>Journal of Controlled Release</i> , 2021, 337, 285-295.	4.8	11
772	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta Oncologica</i> , 2021, 60, 1565-1571.	0.8	2
773	Research progress in the application of bile acid-drug conjugates: A "trojan horse" strategy. <i>Steroids</i> , 2021, 173, 108879.	0.8	7
774	Crossing the blood-brain barrier with graphene nanostructures. <i>Materials Today</i> , 2021, 51, 393-401.	8.3	22
775	The Role of Extracellular Vesicles in the Developing Brain: Current Perspective and Promising Source of Biomarkers and Therapy for Perinatal Brain Injury. <i>Frontiers in Neuroscience</i> , 2021, 15, 744840.	1.4	7
776	Thinking outside the blood: Perspectives on tissue-resident <i>Trypanosoma brucei</i> . <i>PLoS Pathogens</i> , 2021, 17, e1009866.	2.1	25
778	The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2043-2056.	5.7	14
779	Microfluidic Preparation of Janus Microparticles With Temperature and pH Triggered Degradation Properties. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 756758.	2.0	9

#	ARTICLE	IF	CITATIONS
780	Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy–Lysosome Pathway. <i>Biochemistry</i> , 2023, 62, 580-587.	1.2	8
781	Reversibly Modulating the Blood–Brain Barrier by Laser Stimulation of Molecular-Targeted Nanoparticles. <i>Nano Letters</i> , 2021, 21, 9805-9815.	4.5	49
782	Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China. <i>Thoracic Cancer</i> , 2021, 12, 3019-3031.	0.8	12
783	Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2021, 16, 100307.	1.3	14
784	The crosstalk between brain and periphery: Implications for brain health and disease. <i>Neuropharmacology</i> , 2021, 197, 108728.	2.0	17
785	The therapeutic triad of extracellular vesicles: As drug targets, as drugs, and as drug carriers. <i>Biochemical Pharmacology</i> , 2021, 192, 114714.	2.0	17
786	How does biological sex affect the physiological response to nanomaterials?. <i>Nano Today</i> , 2021, 41, 101292.	6.2	6
787	Interventions to Improve Recovery After Stroke. , 2022, , 888-899.e6.		0
788	Cognitive effects of nutraceuticals. , 2021, , 41-61.		0
789	Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration. <i>Pharmaceutics</i> , 2021, 13, 169.	2.0	12
790	In Vitro Human Blood-Brain Barrier Model for Drug Permeability Testing. <i>Methods in Molecular Biology</i> , 2021, 2367, 73-85.	0.4	2
791	Glioma stem cells and associated molecular mechanisms in Glioblastoma Chemoresistance. , 2021, , 135-151.		0
792	Modulation of amyloid- $\beta$ aggregation by metal complexes with a dual binding mode and their delivery across the blood–brain barrier using focused ultrasound. <i>Chemical Science</i> , 2021, 12, 9485-9493.	3.7	12
793	Recent Progress in Blood–Brain Barrier and Blood–CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 23-62.	0.2	11
794	Neurodegenerative Diseases: The Real Problem and Nanobiotechnological Solutions. , 2019, , 1-17.		3
795	The Blood-Brain Barrier in Glioblastoma: Pathology and Therapeutic Implications. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 69-87.	0.1	2
796	The Advances of Biomacromolecule-based Nanomedicine in Brain Disease. , 2019, , 181-208.		2
797	Studies of Metabolism Using $^{13}\text{C}$ MRS of Hyperpolarized Probes. <i>Methods in Enzymology</i> , 2015, 561, 1-71.	0.4	42

#	ARTICLE	IF	CITATIONS
798	Targeted nano-drug delivery system for glioblastoma therapy: In vitro and in vivo study. Journal of Drug Delivery Science and Technology, 2020, 60, 102039.	1.4	11
799	Mathematical modeling and simulation of molecular mass transfer across blood brain barrier in brain capillary. Journal of Molecular Liquids, 2020, 310, 113254.	2.3	12
800	The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102222.	1.7	9
801	Brain Radiation Induced Extracranial Abscopal Effects in Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 836-845.	0.6	4
802	Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS. Journal of General Virology, 2019, 100, 1171-1186.	1.3	19
804	Particle trapping in merging flow junctions by fluid-solute-colloid-boundary interactions. Physical Review Fluids, 2020, 5, .	1.0	12
805	Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. Journal of Clinical Investigation, 2014, 124, 1199-1213.	3.9	88
806	A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier. Journal of Clinical Investigation, 2016, 126, 1717-1733.	3.9	66
807	Drug Delivery to the Central Nervous System. , 2016, , 361-374.		2
808	Catheter placement selection for convection-enhanced delivery of therapeutic agents to brain tumors. F1000Research, 0, 9, 1415.	0.8	3
809	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget, 2017, 8, 111190-111212.	0.8	26
811	A Translational View of Peptide Treatment of Neurological Disorders. Current Medicinal Chemistry, 2014, 21, 2583-2590.	1.2	2
812	Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems. Current Medicinal Chemistry, 2020, 27, 599-629.	1.2	11
813	Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?. Current Pharmaceutical Design, 2014, 20, 1422-1449.	0.9	201
814	Biotin and Glutathione Targeting of Solid Nanoparticles to Cross Human Brain Endothelial Cells. Current Pharmaceutical Design, 2017, 23, 4198-4205.	0.9	19
815	Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins. Current Pharmaceutical Design, 2019, 24, 4932-4946.	0.9	29
816	Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS. Current Pharmaceutical Design, 2019, 25, 3983-3996.	0.9	14
817	Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. Current Pharmaceutical Design, 2020, 25, 4510-4522.	0.9	17

#	ARTICLE	IF	CITATIONS
818	<sub>D</sub>PepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier. <i>Current Pharmaceutical Design</i> , 2020, 26, 1495-1506.	0.9	17
819	Understanding the Pharmaceutical Aspects of Dendrimers for the Delivery of Anticancer Drugs. <i>Current Drug Targets</i> , 2020, 21, 528-540.	1.0	21
820	Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2762-2776.	1.0	4
821	Analysis of the Applicability and Use of Lipinski's Rule for Central Nervous System Drugs. <i>Letters in Drug Design and Discovery</i> , 2016, 13, 999-1006.	0.4	25
823	Exosomes: from biology to clinics. <i>Genes and Cells</i> , 2017, 12, 7-19.	0.2	7
824	Permeability of the Blood-Brain Barrier and Transport of Nanobodies Across the Blood-Brain Barrier. <i>Folia Veterinaria</i> , 2018, 62, 59-66.	0.2	5
825	La pharmacologie des antibiotiques dans le liquide cÃ©rÃ©brospinal. <i>Medecine Intensive Reanimation</i> , 2019, 28, 371-379.	0.1	2
826	Therapeutic Applications of Ultrasound in Neurological Diseases. <i>Journal of Neurosonology and Neuroimaging</i> , 2019, 11, 62-72.	0.0	8
827	Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The Implication of Nanotechnology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 196.	1.8	51
828	A New Transmucous-Buccal Formulation of Acetaminophen for Acute Traumatic Pain: A Non-inferiority, Randomized, Double-Blind, Clinical Trial. <i>Pain Physician</i> , 2015, 3;18, 249-257.	0.3	11
829	Involvement of a Novel Organic Cation Transporter in Paeonol Transport Across the Blood-Brain Barrier. <i>Biomolecules and Therapeutics</i> , 2019, 27, 290-301.	1.1	17
830	Advances in regenerative therapies for spinal cord injury: a biomaterials approach. <i>Neural Regeneration Research</i> , 2015, 10, 726.	1.6	134
831	Advances in Neurotherapeutic Delivery Technologies. , 0, , .		2
832	Is Entresto good for the brain?. <i>World Journal of Cardiology</i> , 2017, 9, 594.	0.5	15
833	Delivery of synthetic mRNAs for tissue regeneration. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 114007.	6.6	18
834	ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. <i>Pharmacological Research</i> , 2022, 178, 105954.	3.1	9
835	Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100426.	1.1	10
836	Sustained A1 Adenosine Receptor Antagonist Drug Release from Nanoparticles Functionalized by a Neural Tracing Protein. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4438-4448.	1.7	5

#	ARTICLE	IF	CITATIONS
837	Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening. <i>Pharmaceutics</i> , 2021, 13, 1598.	2.0	10
838	From Neurodevelopmental to Neurodegenerative Disorders: The Vascular Continuum. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 749026.	1.7	34
839	Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy. <i>World Journal of Oncology</i> , 2013, 4, 122-125.	0.6	0
840	Research Progress of the Effects of Traditional Chinese Medicine and Its Active Ingredients on the Blood Brain Barrier. <i>Pharmacy Information</i> , 2013, 02, 12-18.	0.1	0
841	Active Targeting. , 2013, , 337-374.		0
842	Barrier Signalling. <i>Nanomedicine and Nanotoxicology</i> , 2014, , 245-258.	0.1	0
843	Clinical, Imaging and Pathological Characteristics of Brain Implanted Polylactic Co-Glycolic Acid Polymers Conjugated with Temozolomide. <i>Journal of Veterinary Science &amp; Technology</i> , 2015, 07, .	0.3	1
844	Bloodâ€“Brain Barrier Targeting of Therapeutic Lysosomal Enzymes. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 41-62.	0.2	0
847	8 Role of cell death pathways in response to photodynamic therapy in gliomas. <i>Series in Cellular and Clinical Imaging</i> , 2017, , 131-148.	0.2	0
850	Brain Cancer Receptors and Targeting Strategies. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2019, , 45-78.	0.2	1
851	Extracranial Abscopal Responses after Radiation Therapy for Intracranial Metastases: A Review of the Clinical Literature and Commentary on Mechanism. <i>Cureus</i> , 2019, 11, e4207.	0.2	7
853	Deregulation of BCL2 family genes in glioblastoma cells consequent to poly(butyl cyanoacrylate) nanoparticles treatment. <i>Micro and Nano Letters</i> , 2019, 14, 1102-1106.	0.6	0
854	Extracranial Abscopal Effects Induced by Brain Radiation in Advanced Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 951-957.	0.6	5
857	Novel Diagnostic and Therapeutic Immunologic Strategies to Overcome Infectious, Oncologic and Neurodegenerative Disorders. , 2020, , 436-459.		0
858	Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 105-114.	0.4	0
861	Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. <i>Cancers</i> , 2021, 13, 5387.	1.7	11
862	A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimerâ€™s Disease. <i>Molecular Pharmaceutics</i> , 2021, 18, 4237-4255.	2.3	5
863	Multifunctional Nanopolymers for Bloodâ€“Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1. <i>Nanomaterials</i> , 2021, 11, 2892.	1.9	9

#	ARTICLE	IF	CITATIONS
864	Advances in extracellular vesicles analysis. <i>Advances in Clinical Chemistry</i> , 2020, 97, 73-116.	1.8	7
865	Nanoformulations in Human Health Conditions: The Paradigm Shift. , 2020, , 13-42.		0
866	Eksozomlar: KompozisyonlarÄ±, Biyolojik FonksiyonlarÄ± ve Biyoaktif BileÅŸiklerin TaÅŸınmasÄ±ndaki Potansiyelleri. <i>Akademik GÄ±da</i> , 0, , 421-432.	0.5	0
867	The Role of P-Glycoprotein at the Blood-Brain Barrier in Neurological and Psychiatric Disease. , 2021, , 45-81.		0
868	Strategies to Enhance the Distribution of Therapeutic Nanoparticles in the Brain by Convection Enhanced Delivery. <i>NeuroMethods</i> , 2021, , 179-204.	0.2	1
869	Advances and challenges toward neural regenerative medicine. , 2020, , 1-23.		1
871	Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2021, 13, 1897.	2.0	27
873	Neuropathological Findings in Drug Abusers. , 2021, , 89-103.		0
875	Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. <i>Current Pharmaceutical Design</i> , 2016, 22, 1177-1193.	0.9	95
876	Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model. <i>Current Alzheimer Research</i> , 2016, 13, 663-77.	0.7	4
878	Impairment of human dopaminergic neurons at different developmental stages by perfluoro-octanoic acid (PFOA) and differential human brain areas accumulation of perfluoroalkyl chemicals. <i>Environment International</i> , 2022, 158, 106982.	4.8	32
879	Surface engineering of nanoparticles for imparting multifunctionality. , 2022, , 181-210.		4
880	Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. <i>Experimental Neurology</i> , 2022, 348, 113923.	2.0	10
881	Special delEVery: Extracellular Vesicles as Promising Delivery Platform to the Brain. <i>Biomedicines</i> , 2021, 9, 1734.	1.4	16
882	Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v133-v143.	0.4	11
883	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114033.	6.6	5
884	Vitex negundo L. Essential Oil: Odorant Binding Protein Efficiency Using Molecular Docking Approach and Studies of the Mosquito Repellent. <i>Insects</i> , 2021, 12, 1061.	1.0	10
885	Emerging Antioxidant Paradigm of Mesenchymal Stem Cell-Derived Exosome Therapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 727272.	1.5	22



#	ARTICLE	IF	CITATIONS
886	Nanomedicine as a future therapeutic approach for treating meningitis. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 67, 102968.	1.4	0
887	Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model. <i>Investigational New Drugs</i> , 2022, 40, 255-264.	1.2	9
888	Neuroprotective effects of an in vitro BBB permeable phenoxythiophene sulfonamide small molecule in glutamate-induced oxidative injury. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 79.	0.8	1
889	Editorial: Organization and Functional Properties of the Blood-Brain Barrier. <i>Frontiers in Physiology</i> , 2021, 12, 796030.	1.3	1
890	Drug delivery to the central nervous system. <i>Nature Reviews Materials</i> , 2022, 7, 314-331.	23.3	82
891	Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain. <i>AAPS PharmSciTech</i> , 2022, 23, 11.	1.5	18
892	Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier. <i>Theranostics</i> , 2021, 11, 10148-10170.	4.6	18
895	Considerations When Developing Blood-Brain Barrier Crossing Drug Delivery Technology. <i>Handbook of Experimental Pharmacology</i> , 2021, , 83-95.	0.9	1
896	Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications. <i>Pharmaceutics</i> , 2022, 15, 76.	1.7	12
897	In silico, ADMET and Docking Analysis for the Compounds of Chloroform Extract of <i>Tinospora cardifolia</i> (Wild.) Identified by GC-MS and Spectral Analysis for Antidiabetic and Anti-Inflammatory Activity. <i>Asian Journal of Chemistry</i> , 2022, 34, 342-354.	0.1	1
898	Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier. <i>Free Radical Biology and Medicine</i> , 2022, 178, 189-201.	1.3	15
899	Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders. <i>Biomedicines</i> , 2022, 10, 158.	1.4	11
900	An Overview of Nanotechnologies for Drug Delivery to the Brain. <i>Pharmaceutics</i> , 2022, 14, 224.	2.0	34
901	Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System. <i>Pharmaceutics</i> , 2022, 14, 165.	2.0	6
902	Nanotech-based Food: An Initiative for Alternative Pharmaceuticals. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1739-1749.	0.9	1
903	Methamphetamine enhances caveolar transport of therapeutic agents across the rodent blood-brain barrier. <i>Cell Reports Medicine</i> , 2022, 3, 100497.	3.3	4
904	phytochemdb: a platform for virtual screening and computer-aided drug designing. <i>Database: the Journal of Biological Databases and Curation</i> , 2022, 2022, .	1.4	13
905	Extracellular Vesicle Delivery of Neferine for the Attenuation of Neurodegenerative Disease Proteins and Motor Deficit in an Alzheimer's Disease Mouse Model. <i>Pharmaceutics</i> , 2022, 15, 83.	1.7	19

#	ARTICLE	IF	CITATIONS
906	In Vitro Evaluation of the Cytotoxic Effect of Streptococcus pyogenes Strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Factor and Chemotherapy on the C6 Glioma Cell Line. <i>Molecules</i> , 2022, 27, 569.	1.7	6
907	Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 41, 102523.	1.7	6
908	Nanomedicine for brain cancer. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114115.	6.6	57
909	Antimicrobial peptide-based materials: opportunities and challenges. <i>Journal of Materials Chemistry B</i> , 2022, 10, 2384-2429.	2.9	47
910	Is oral lipid-based delivery for drug targeting to the brain feasible?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 112-122.	2.0	8
911	Identification of a small compound that specifically inhibits Zika virus in vitro and in vivo by targeting the NS2B-NS3 protease. <i>Antiviral Research</i> , 2022, 199, 105255.	1.9	3
912	A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1851.	1.8	128
913	The Immuno-Modulation Effect of Macrophage-Derived Extracellular Vesicles in Chronic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 785728.	2.2	14
914	Drug Delivery Challenges in Brain Disorders across the Blood-Brain Barrier: Novel Methods and Future Considerations for Improved Therapy. <i>Biomedicines</i> , 2021, 9, 1834.	1.4	32
915	Recent trends of theranostic applications of nanoparticles in neurodegenerative disorders. , 2022, , 151-164.		0
917	<i>In-Silico</i> Analysis of VP4 Protein Causing Pathogenesis in <i>Rotavirus</i> and Its Interaction Studies. <i>Science of Advanced Materials</i> , 2022, 14, 67-79.	0.1	3
918	Making waves: how ultrasound-targeted drug delivery is changing pharmaceutical approaches. <i>Materials Advances</i> , 2022, 3, 3023-3040.	2.6	31
919	A human brain vascular atlas reveals diverse mediators of Alzheimer's risk. <i>Nature</i> , 2022, 603, 885-892.	18.7	294
920	Exosomes and Other Extracellular Vesicles with High Therapeutic Potential: Their Applications in Oncology, Neurology, and Dermatology. <i>Molecules</i> , 2022, 27, 1303.	1.7	20
921	Comparison of Comprehensive Screening Results in Postmortem Blood and Brain Tissue by UHPLC-QTOF-MS. <i>Journal of Analytical Toxicology</i> , 2023, 46, 1053-1058.	1.7	2
922	Immunotherapeutic Approaches for Glioblastoma Treatment. <i>Biomedicines</i> , 2022, 10, 427.	1.4	6
923	Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2023, 30, 255-270.	1.2	5
924	Nanotherapeutics and the Brain. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2022, 13, 325-346.	3.3	4

#	ARTICLE	IF	CITATIONS
925	Extracellular Vesicles: Emerging Roles in Developing Therapeutic Approach and Delivery Tool of Chinese Herbal Medicine for the Treatment of Depressive Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 843412.	1.6	5
926	Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, , e29664.	0.8	1
927	Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles. <i>Journal of Controlled Release</i> , 2022, 343, 777-797.	4.8	23
928	Identifying potential natural inhibitors of <i>Brucella melitensis</i> Methionyl-tRNA synthetase through an in-silico approach. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0009799.	1.3	4
930	Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2121609119.	3.3	14
931	Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles. <i>Pharmaceutics</i> , 2022, 15, 358.	1.7	19
932	The blood-brain barrier in aging and neurodegeneration. <i>Molecular Psychiatry</i> , 2022, 27, 2659-2673.	4.1	141
933	PCSK9 acts as a key regulator of A $\beta$ clearance across the blood-brain barrier. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 212.	2.4	16
934	Heparin-Derived Theranostic Nanoprobes Overcome the Blood-Brain Barrier and Target Glioma in Murine Model. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	7
935	Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases. <i>Frontiers in Immunology</i> , 2022, 13, 852811.	2.2	6
936	Dendrimers as Antiamyloid Agents. <i>Pharmaceutics</i> , 2022, 14, 760.	2.0	11
938	Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, .	1.1	25
939	Alcohol-Induced Alterations in the Vascular Basement Membrane in the Substantia Nigra of the Adult Human Brain. <i>Biomedicines</i> , 2022, 10, 830.	1.4	1
940	Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4153.	1.8	74
941	Sex differences in the blood-brain barrier: Implications for mental health. <i>Frontiers in Neuroendocrinology</i> , 2022, 65, 100989.	2.5	31
942	Enhanced anti-angiogenic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. <i>MAbs</i> , 2022, 14, 2057269.	2.6	8
943	Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules. <i>Bioinformatics</i> , 2022, 38, 2826-2831.	1.8	7
944	Breaking through the barrier: Modelling and exploiting the physical microenvironment to enhance drug transport and efficacy. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114183.	6.6	10

#	ARTICLE	IF	CITATIONS
945	Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114234.	6.6	21
946	Synthesis and in vitro evaluation of a novel thienopyrimidine with phototoxicity towards rat glioma F98 cells. <i>Journal of Photochemistry and Photobiology</i> , 2022, 10, 100114.	1.1	0
947	Molecular Informatics of Trypanothione Reductase of <i>Leishmania major</i> Reveals Novel Chromen-2-One Analogues as Potential Leishmanicides. , 0, , .		0
948	Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13160.	1.8	17
949	Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 739765.	1.3	6
950	Modeling ischemic stroke in a triculture neurovascular unit on-a-chip. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 59.	2.4	30
951	Decabromodiphenyl Ethane Mainly Affected the Muscle Contraction and Reproductive Endocrine System in Female Adult Zebrafish. <i>Environmental Science &amp; Technology</i> , 2022, 56, 470-479.	4.6	27
952	The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Bloodâ€“Brain Barrier Disruption Without Evidence of Early Brain Injury. <i>Frontiers in Neuroscience</i> , 2021, 15, 791709.	1.4	9
953	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. <i>Frontiers in Neurology</i> , 2022, 13, 870799.	1.1	4
954	Intrathecal Medication From Pain Pump Caused Prolonged Alteration in Mental Status Following Decompression of Severe Spinal Stenosis. <i>Cureus</i> , 2022, 14, e24180.	0.2	0
955	Engineered biomimetic drug-delivery systems for ischemic stroke therapy. <i>Medicine in Drug Discovery</i> , 2022, 15, 100129.	2.3	7
956	Multidrug Resistance-1 C3435T Polymorphism and Carbamazepine Plasma Level in Indonesian Temporal Lobe Epilepsy Patients. <i>Current Drug Safety</i> , 2022, 17, .	0.3	0
957	Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 71, 103315.	1.4	0
966	Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp. <i>Current Pharmaceutical Design</i> , 2022, 28, 969-980.	0.9	11
967	Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. <i>Molecular Pharmaceutics</i> , 2022, 19, 1952-1976.	2.3	5
968	Advances in Hydrogel-Based Microfluidic Bloodâ€“Brain-Barrier Models in Oncology Research. <i>Pharmaceutics</i> , 2022, 14, 993.	2.0	12
969	A novel strategy for delivering <i>N</i> -mannanâ€“ <i>P</i> -glycosylated C2 proteins across the bloodâ€“brain barrier using the brain endothelialâ€“specific AAVâ€“BR1 virus. <i>Journal of Neurochemistry</i> , 2023, 164, 6-28.	2.1	4
970	Biosensors Integration in Bloodâ€“Brain Barrier-on-a-Chip: Emerging Platform for Monitoring Neurodegenerative Diseases. <i>ACS Sensors</i> , 2022, 7, 1237-1247.	4.0	25

#	ARTICLE	IF	CITATIONS
971	Research Progress on Nanoplatfoms and Nanotherapeutic Strategies in Treating Glioma. <i>Molecular Pharmaceutics</i> , 2022, 19, 1927-1951.	2.3	13
972	Advances in designing of polymeric micelles for biomedical application in brain related diseases. <i>Chemico-Biological Interactions</i> , 2022, 361, 109960.	1.7	21
973	Discovery of 1 $\beta$ -(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3 $\beta$ -pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11 $\beta$ -HSD1 using a scaffold-hopping approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 69, 128782.	1.0	3
974	Shedding Light on the Blood $\rightarrow$ Brain Barrier Transport with Two-Photon Microscopy In Vivo. <i>Pharmaceutical Research</i> , 2022, 39, 1457-1468.	1.7	5
975	Pulmonary Pharmacokinetics of Polymer Lung Surfactants Following Pharyngeal Administration in Mice. <i>Biomacromolecules</i> , 2022, 23, 2471-2484.	2.6	6
976	Transport of Transferrin Receptor-Targeted Antibodies Through the Blood-Brain Barrier for Drug Delivery to the Brain. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2022, , 527-549.	0.2	1
977	Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. <i>Therapeutic Delivery</i> , 0, , .	1.2	4
978	Nt5e deficiency does not affect post-stroke inflammation and lesion size in a murine ischemia/reperfusion stroke model. <i>IScience</i> , 2022, 25, 104470.	1.9	3
979	Glutathione responsive nanocarrier based on viologen resorcinarene cavitand and 1-allylthymine. <i>New Journal of Chemistry</i> , 0, , .	1.4	0
980	Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114362.	6.6	17
981	Advances of nano drug delivery system for the theranostics of ischemic stroke. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	13
982	Microfluidic Organ-on-a-Chip System for Disease Modeling and Drug Development. <i>Biosensors</i> , 2022, 12, 370.	2.3	25
984	Blood $\rightarrow$ brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. <i>Molecular Brain</i> , 2022, 15, .	1.3	33
985	The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120316.	0.3	10
986	Central Nervous System Bioavailability. , 2022, , 233-242.		0
987	Challenges in targeting to brain and brain tumors. , 2022, , 51-68.		0
988	Hybrid nanoparticles to cross the blood $\rightarrow$ brain barrier. , 2022, , 565-586.		3
989	Selective brain entry of lipid nanoparticles in haemorrhagic stroke is linked to biphasic blood-brain barrier disruption. <i>Theranostics</i> , 2022, 12, 4477-4497.	4.6	7

#	ARTICLE	IF	CITATIONS
990	Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. <i>Theranostics</i> , 2022, 12, 4734-4752.	4.6	33
991	Dendrimers as carriers for active targeting of brain tumors. , 2022, , 401-430.		0
992	Biomedical applications of nanocarriers in brain tumor targeting. , 2022, , 205-233.		0
993	The Phytochemical Potential for Brain Disease Therapy and the Possible Nanodelivery Solutions for Brain Access. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
994	Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs). <i>Pharmaceutics</i> , 2022, 14, 1234.	2.0	3
995	A Historical Review of Brain Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 1283.	2.0	65
996	Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2022, 28, 3329-3341.	3.2	6
997	Historical and current perspectives on blood endothelial cell heterogeneity in the brain. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	12
999	Taking Advantages of Bloodâ€“Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1071.	1.1	9
1000	The AMPK-SIRT1-FoxO1-NF- $\kappa$ B signaling pathway participates in hesperetin-mediated neuroprotective effects against traumatic brain injury via the NLRP3 inflammasome. <i>Immunopharmacology and Immunotoxicology</i> , 2022, 44, 970-983.	1.1	8
1001	Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	4
1002	In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus. <i>Molecules</i> , 2022, 27, 4515.	1.7	4
1003	Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. <i>Frontiers in Aging</i> , 0, 3, .	1.2	35
1004	Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1866-1886.	5.7	23
1005	Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery in Neurodegenerative Disorders. <i>Biomedicines</i> , 2022, 10, 1706.	1.4	17
1006	Computational Assessment of Different Structural Models for Claudin-5 Complexes in Bloodâ€“Brain Barrier Tight Junctions. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2140-2153.	1.7	10
1007	Transport of cationic liposomes in a human blood brain barrier model: Role of the stereochemistry of the gemini amphiphile on liposome biological features. <i>Journal of Colloid and Interface Science</i> , 2022, 627, 283-298.	5.0	9
1008	Functional Expression of Multidrug-Resistance (MDR) Transporters in Developing Human Fetal Brain Endothelial Cells. <i>Cells</i> , 2022, 11, 2259.	1.8	6

#	ARTICLE	IF	CITATIONS
1009	Investigation of some diethyl (4-(dimethylamino)-2,5-dihydro-2,5-dioxo-1-phenyl-1H-pyrrol-3-yl)(hydroxy)methylphosphonate derivatives for In silico pharmacokinetic profile and In vitro anticancer activity. <i>Chemical Papers</i> , 0, , .	1.0	1
1010	Neuroprotective Potential of Thinned Peaches Extracts Obtained by Pressurized Liquid Extraction after Different Drying Processes. <i>Foods</i> , 2022, 11, 2464.	1.9	3
1011	Excited-State Intramolecular Hydrogen Transfer of Compact Molecules Controls Amyloid Aggregation Profiles. <i>Jacs Au</i> , 2022, 2, 2001-2012.	3.6	5
1012	Organ-on-a-Chip Models of the Blood-Brain Barrier: Recent Advances and Future Prospects. <i>Small</i> , 2022, 18, .	5.2	14
1013	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9305.	1.8	13
1014	Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. <i>MABs</i> , 2022, 14, .	2.6	5
1015	Probing the Interactions of Lamotrigine and Phenobarbital with Tau Protein: Experimental and Molecular Modeling Studies. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.3	3
1016	Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases. <i>Journal of Functional Biomaterials</i> , 2022, 13, 125.	1.8	17
1017	The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10136.	1.8	6
1018	Modeling transport of soluble proteins and metabolites in the brain. , 2022, , 493-508.		0
1019	Neuropathologische Befunde bei Drogenkonsumenten. , 2022, , 91-106.		0
1020	In Silico Studies of Bioactive Compounds from <i>Alpinia Officinarum</i> as Inhibitors of Zika Virus Protease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1021	Polymeric micelles for oral drug delivery. , 2022, , 89-113.		0
1022	Perfluoroalkyl and polyfluoroalkyl substances (PFASs) crossing the blood-cerebrospinal fluid barrier: Their occurrence in human cerebrospinal fluid. <i>Journal of Hazardous Materials</i> , 2023, 442, 130003.	6.5	10
1023	An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. <i>Cancers</i> , 2022, 14, 4256.	1.7	5
1024	Peripheral interleukin-6-associated microglial QUIN elevation in basolateral amygdala contributed to cognitive dysfunction in a mouse model of postoperative delirium. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1025	Utility of Ghrita in Treatment of Unmada (Unstable Mind) with special reference to Charaka Samhita. <i>Dev Sanskriti Interdisciplinary International Journal</i> , 0, , .	0.0	0
1026	Extracellular vesicle-based drug delivery system boosts phytochemicals' therapeutic effect for neurodegenerative diseases. , 2022, 2, 229-239.		7

#	ARTICLE	IF	CITATIONS
1027	Unique structural features of claudinâ€5 and claudinâ€15 lead to functionally distinct tight junction strand architecture. <i>Annals of the New York Academy of Sciences</i> , 2022, 1517, 225-233.	1.8	6
1028	Neuropharmacological Effects of Terpenoids on Preclinical Animal Models of Psychiatric Disorders: A Review. <i>Antioxidants</i> , 2022, 11, 1834.	2.2	7
1029	Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinsonâ€™s Disease. <i>Applied Biochemistry and Biotechnology</i> , 2023, 195, 639-654.	1.4	3
1030	A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1031	A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimerâ€™s disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	33
1032	NIRâ€Assisted MgOâ€Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease through the Bloodâ€Brain Barrier. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	6
1035	Polymeric Nanoparticles: Prospective on the Synthesis, Characterization and Applications in Nose-to-Brain Drug Delivery. <i>Current Nanoscience</i> , 2023, 19, 663-676.	0.7	1
1036	Choroid plexus-derived extracellular vesicles exhibit brain targeting characteristics. <i>Biomaterials</i> , 2022, 290, 121830.	5.7	6
1037	Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	6
1038	Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics. <i>Oncology Research</i> , 2021, 29, 351-363.	0.6	4
1039	An Up-to-Date Look at In Vitro Models of Nose-to-Brain Drug Delivery. , 2022, , 115-139.		0
1040	Constant-rate perfused array chip for high-throughput screening of drug permeability through brain endothelium. <i>Lab on A Chip</i> , 2022, 22, 4481-4492.	3.1	6
1041	New insight into brain disease therapy: nanomedicines-crossing bloodâ€brain barrier and extracellular space for drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1618-1635.	2.4	10
1042	Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering. <i>Molecular Therapy</i> , 2023, 31, 1207-1224.	3.7	37
1043	Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)â€A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA. <i>Cancers</i> , 2022, 14, 5179.	1.7	5
1045	Aminopeptidase B can bioconvert L-type amino acid transporter 1 (LAT1)-utilizing amide prodrugs in the brain. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1046	Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets. <i>Aging</i> , 2022, 14, 8077-8094.	1.4	1
1048	Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	17



#	ARTICLE	IF	CITATIONS
1049	Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. <i>Med</i> , 2022, 3, 860-882.e15.	2.2	21
1050	Simple and efficient protocol to isolate and culture brain microvascular endothelial cells from newborn mice. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	3
1051	A Comprehensive Study to Unleash the Putative Inhibitors of Serotype2 of Dengue Virus: Insights from an In Silico Structure-Based Drug Discovery. <i>Molecular Biotechnology</i> , 0, , .	1.3	8
1052	Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications. <i>Pharmaceutics</i> , 2022, 14, 2300.	2.0	5
1053	Tumor microenvironment and exosomes in brain metastasis: Molecular mechanisms and clinical application. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1054	Advances in the research of nano delivery systems in ischemic stroke. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
1055	Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. <i>Cancers</i> , 2022, 14, 4920.	1.7	19
1056	Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 272-287.	2.0	6
1057	Role of microRNAs in the regulation of blood-brain barrier function in ischemic stroke and under hypoxic conditions in vitro. <i>Frontiers in Drug Delivery</i> , 0, 2, .	0.4	0
1058	A new host-targeted antiviral cyclolignan (SAU-22.107) for Dengue Virus infection in cell cultures. Potential action mechanisms based on cell imaging. <i>Virus Research</i> , 2023, 323, 198995.	1.1	2
1059	Traumatic Brain Injury-Mediated Neuroinflammation and Neurological Deficits are Improved by 8-Methoxypsoralen Through Modulating PPAR $\gamma$ /NF- $\kappa$ B Pathway. <i>Neurochemical Research</i> , 0, , .	1.6	1
1060	Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies. <i>Journal of Controlled Release</i> , 2022, 352, 121-145.	4.8	10
1061	Central nervous system infections. , 2023, , 221-247.		0
1062	Focal Opening of the Neuronal Plasma Membrane by Shock-induced Bubble Collapse for Drug Delivery. A Coarse-Grained Molecular Dynamic Simulation. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	2
1063	Pharmacology and Mechanism of Action of Drugs. , 2023, , 144-154.		0
1064	Effects of Usnic Acid on Apoptosis and Expression of Bax and Bcl-2 Proteins in Hippocampal CA1 Neurons Following Cerebral Ischemia-Reperfusion. <i>Majallah-i Dānishgāh-i â€™UlĀ«m-i PizishkĀ«i ĀĀm</i> , 2022, 30, 0.1 101-111.		0
1065	WP1234â€”A Novel Anticancer Agent with Bifunctional Activity in a Glioblastoma Model. <i>Biomedicines</i> , 2022, 10, 2799.	1.4	1
1066	Molecular mechanism of virgin coconut oil as a Nsp-3 inhibitor of SARS-CoV-2. <i>Asia-Pacific Journal of Molecular Biology and Biotechnology</i> , 0, , 9-19.	0.2	0

#	ARTICLE	IF	CITATIONS
1067	Extracellular histones as damage-associated molecular patterns in neuroinflammatory responses. <i>Reviews in the Neurosciences</i> , 2023, 34, 533-558.	1.4	6
1068	Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies. <i>Pharmaceutics</i> , 2022, 14, 2370.	2.0	9
1069	CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting. <i>Pharmaceutical Research</i> , 2023, 40, 77-105.	1.7	9
1070	TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems. <i>Pharmaceutical Research</i> , 2023, 40, 245-263.	1.7	4
1071	Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. <i>Advanced Drug Delivery Reviews</i> , 2022, 191, 114619.	6.6	22
1072	Engineering antibody and protein therapeutics to cross the blood–brain barrier. <i>Antibody Therapeutics</i> , 2022, 5, 311-331.	1.2	4
1073	Immunotherapeutic Strategies for Glioma Treatment. , 2022, , .		0
1074	Recent progress in nanomedicines for imaging and therapy of brain tumors. <i>Biomaterials Science</i> , 2023, 11, 1270-1310.	2.6	3
1075	Exosome-based approaches in the management of Alzheimer’s disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 144, 104974.	2.9	11
1076	Safety Pharmacology Evaluation of Biopharmaceuticals. , 2022, , 1-16.		0
1077	Antibody-Based In Vivo Imaging of Central Nervous System Targets—Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines. <i>Pharmaceutics</i> , 2022, 15, 1445.	1.7	7
1078	An Update on Peripheral Blood Extracellular Vesicles as Biomarkers for Parkinson’s Disease Diagnosis. <i>Neuroscience</i> , 2023, 511, 131-146.	1.1	4
1079	Transcriptomic Mapping of Neurotoxicity Pathways in the Rat Brain in Response to Intraventricular Polymyxin B. <i>Molecular Neurobiology</i> , 2023, 60, 1317-1330.	1.9	1
1080	Molecular Mechanism and Role of Japanese Encephalitis Virus Infection in Central Nervous System-Mediated Diseases. <i>Viruses</i> , 2022, 14, 2686.	1.5	8
1081	Neuroprotective effects of bornyl acetate on experimental autoimmune encephalomyelitis via anti-inflammatory effects and maintaining blood-brain-barrier integrity. <i>Phytomedicine</i> , 2023, 112, 154569.	2.3	6
1082	Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. <i>Molecules</i> , 2022, 27, 8891.	1.7	6
1083	Computational screening for new neuroprotective ingredients against Alzheimer’s disease from bilberry by cheminformatics approaches. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
1084	<sc>CXCR4</sc> antagonists disrupt leukaemia–meningeal cell adhesion and attenuate chemoresistance. <i>British Journal of Haematology</i> , 2023, 201, 459-469.	1.2	3

#	ARTICLE	IF	CITATIONS
1085	A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain. <i>Med</i> , 2022, 3, 815-817.	2.2	0
1086	Recent Development of Hybrids and Derivatives of Resveratrol in Neurodegenerative Diseases. , 2022, , 27-72.		0
1087	Brain organoid-on-a-chip: A next-generation human brain avatar for recapitulating human brain physiology and pathology. <i>Biomicrofluidics</i> , 2022, 16, .	1.2	8
1088	Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. <i>Neuro-Oncology</i> , 2023, 25, 1113-1122.	0.6	6
1089	Antioxidant Intervention to Improve Cognition in the Aging Brain: The Example of Hydroxytyrosol and Resveratrol. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15674.	1.8	11
1090	In-depth mapping of protein localizations in whole tissue by micro-scaffold assisted spatial proteomics (MASP). <i>Nature Communications</i> , 2022, 13, .	5.8	8
1091	Photostable Small-Molecule NIR-II Fluorescent Scaffolds that Cross the Blood-Brain Barrier for Noninvasive Brain Imaging. <i>Journal of the American Chemical Society</i> , 2022, 144, 23668-23676.	6.6	25
1092	Natural and engineered cyclodipeptides: Biosynthesis, chemical diversity, and engineering strategies for diversification and high-yield bioproduction.. <i>Engineering Microbiology</i> , 2023, 3, 100067.	2.2	6
1093	Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective. <i>International Journal of Pharmaceutics</i> , 2023, 633, 122614.	2.6	2
1094	Neuroprotective Effects of Licochalcone D in Oxidative-Stress-Induced Primitive Neural Stem Cells from Parkinson's Disease Patient-Derived iPSCs. <i>Biomedicines</i> , 2023, 11, 228.	1.4	0
1095	Considering developmental neurotoxicity <i>in vitro</i> data for human health risk assessment using physiologically-based kinetic modeling: deltamethrin case study. <i>Toxicological Sciences</i> , 2023, 192, 59-70.	1.4	1
1096	Morphological and Functional Effects of Ultrasound on Blood-Brain Barrier Transitory Opening: An In Vitro Study on Rat Brain Endothelial Cells. <i>Cells</i> , 2023, 12, 192.	1.8	0
1097	Suitability of cardiac blood, brain tissue, and muscle tissue as alternative matrices for toxicological evaluation in postmortem cases. <i>Drug Testing and Analysis</i> , 2023, 15, 529-538.	1.6	1
1098	Biochemistry of exosomes and their theranostic potential in human diseases. <i>Life Sciences</i> , 2023, 315, 121369.	2.0	5
1099	Repurposing Mitragynine as Anti-SARS-CoV-2 Agent Evidenced by In Silico Predictive Approach. <i>Malaysian Journal of Fundamental and Applied Sciences</i> , 2022, 18, 644-653.	0.4	0
1100	Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1101	Advances in Antibody-Based Therapeutics for Cerebral Ischemia. <i>Pharmaceutics</i> , 2023, 15, 145.	2.0	1
1104	The role of blood-brain and blood-retinal barriers in drug delivery. , 2023, , 133-154.		2

#	ARTICLE	IF	CITATIONS
1105	Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1106	Transporter-Mediated Drug Delivery. <i>Molecules</i> , 2023, 28, 1151.	1.7	13
1107	Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. <i>Biomaterials Science</i> , 2023, 11, 3394-3413.	2.6	11
1108	Real-Time Intravital Imaging of Acoustic Cluster Therapy-Induced Vascular Effects in the Murine Brain. <i>Ultrasound in Medicine and Biology</i> , 2023, 49, 1212-1226.	0.7	1
1109	Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. <i>Advances in Oncology</i> , 2023, 3, 77-86.	0.1	1
1110	The protective effect of <i>Allium chinense</i> on anti-cerebral anoxia through regulating NLRP3/NF- $\kappa$ B. <i>Industrial Crops and Products</i> , 2023, 196, 116499.	2.5	0
1111	From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. <i>Advanced Drug Delivery Reviews</i> , 2023, 196, 114777.	6.6	8
1112	Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	3
1113	Nanomedicine based strategies for oligonucleotide traversal across the blood-brain barrier. <i>Journal of Controlled Release</i> , 2023, 354, 554-571.	4.8	7
1114	Recent advances in the <i>in vitro</i> and <i>in vivo</i> methods to assess impact of $\alpha$ -glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition. <i>Biopharmaceutics and Drug Disposition</i> , 2023, 44, 7-25.	1.1	4
1115	Nanotechnology-based drug delivery for the treatment of CNS disorders. <i>Translational Neuroscience</i> , 2022, 13, 527-546.	0.7	13
1116	Targeting adverse effects of antiepileptic medication on offspring: current evidence and new strategies for safety. <i>Expert Review of Neurotherapeutics</i> , 2023, 23, 141-156.	1.4	0
1117	Towards early detection of neurodegenerative diseases: A gut feeling. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	7
1118	<i>Nigella sativa</i> and its nano-mediated approach toward management of neurodegenerative disorders: A review. , 2023, 9, 111-123.		0
1119	Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3390.	1.8	8
1120	Possible contrast extravasation after mechanical thrombectomy in an infected aneurysm distal to the occlusion: a case report. <i>Nosotchu</i> , 2023, , .	0.0	0
1122	Current state of phoenixin—the implications of the pleiotropic peptide in stress and its potential as a therapeutic target. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1123	Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation. , 2023, , 1-24.		0

#	ARTICLE	IF	CITATIONS
1124	Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases. <i>Pharmaceutics</i> , 2023, 15, 621.	2.0	9
1125	Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy. <i>Journal of Controlled Release</i> , 2023, 355, 474-488.	4.8	3
1126	Towards standardization of the parameters for opening the blood-brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1127	Brain-Penetrating and Disease Site-Targeting Manganese Dioxide-Polymer-Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways. <i>Advanced Science</i> , 2023, 10, .	5.6	10
1128	Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2023, 10, .	3.1	5
1129	Standardized Preclinical <i>In Vitro</i> Blood-Brain Barrier Mouse Assay Validates Endocytosis-Dependent Antibody Transcytosis Using Transferrin-Receptor-Mediated Pathways. <i>Molecular Pharmaceutics</i> , 2023, 20, 1564-1576.	2.3	3
1130	<i>Homo medicus</i> : The transition to meat eating increased pathogen pressure and the use of pharmacological plants in <i>Homo</i> . <i>American Journal of Biological Anthropology</i> , 2023, 180, 589-617.	0.6	4
1131	Physicochemical assessment and <i>insilico</i> studies on the interaction of 5-HT <sub>2c</sub> receptor with herbal medication bioactive compounds used in the treatment of premature ejaculation. <i>ChemistrySelect</i> , 2024, 9, 1083-1116.	0.7	0
1132	Improved Boron Neutron Capture Therapy Using Integrin $\alpha_5\beta_1$ -Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model. <i>Biology</i> , 2023, 12, 377.	1.3	5
1133	Exosome Mediated Cancer Therapeutic Approach: Present Status and Future Prospectives. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 363-373.	0.5	6
1135	Pharmacokinetic-pharmacodynamic modeling before clinical study. <i>Paediatric Anaesthesia</i> , 2023, 33, 276-277.	0.6	0
1136	Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs: The role of Polypharmacology and Cholinesterase inhibitors. <i>ChemistrySelect</i> , 2023, 8, .	0.7	6
1138	In silico studies of bioactive compounds from <i>Alpinia officinarum</i> as inhibitors of Zika virus protease. <i>Informatics in Medicine Unlocked</i> , 2023, 38, 101214.	1.9	2
1139	Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients. <i>Annals of Medicine</i> , 2023, 55, 1018-1028.	1.5	1
1140	Transcranial application of magnetic pulses for improving brain drug delivery efficiency via intranasal injection of magnetic nanoparticles. <i>Biomedical Engineering Letters</i> , 0, , .	2.1	0
1141	Transport of nanocarriers to brain for treatment of glioblastoma multiforme: Routes and challenges. , 2023, 1, 100005.		3
1142	An Overview on Nanocarriers for Nasal Delivery. , 2023, , 141-168.		0
1143	Ligand-based pharmacophore modelling, virtual screening and docking studies to identify potential compounds against FtsZ of <i>Mycobacterium tuberculosis</i> . <i>Indian Journal of Tuberculosis</i> , 2023, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1144	Neuroanatomical Tract Tracers: Not Just for Neural Tracing Anymore. ACS Applied Bio Materials, 2023, 6, 1380-1397.	2.3	1
1145	2D-QSAR, molecular docking and MD simulation based virtual screening of the herbal molecules against Alzheimer's disorder: an approach to predict CNS activity. Journal of Biomolecular Structure and Dynamics, 2024, 42, 148-162.	2.0	4
1146	BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer's disease. Journal of Nanobiotechnology, 2023, 21, .	4.2	23
1147	Biomedical applications of magnetic nanocarriers—a review. , 2023, , 195-212.		0
1149	Ferulic acid-loaded polymeric nanoparticles prepared from nano-emulsion templates facilitate internalisation across the blood-brain barrier in model membranes. Nanoscale, 2023, 15, 7929-7944.	2.8	7
1150	Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain. Advanced Drug Delivery Reviews, 2023, 197, 114820.	6.6	8
1151	Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. Frontiers in Oncology, 0, 13, .	1.3	3
1152	Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?. Neural Regeneration Research, 2024, 19, 29-34.	1.6	2
1153	Combined effects of spike-timing-dependent plasticity and homeostatic structural plasticity on coherence resonance. Physical Review E, 2023, 107, .	0.8	1
1154	Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration. Frontiers in Immunology, 0, 14, .	2.2	1
1156	Endocrine Regulation of Microvascular Receptor-Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9-Mediated Regulation. Pharmaceutics, 2023, 15, 1268.	2.0	0
1157	Vector enabled CRISPR gene editing – A revolutionary strategy for targeting the diversity of brain pathologies. Coordination Chemistry Reviews, 2023, 487, 215172.	9.5	0
1158	Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature. Biomedicines, 2023, 11, 1225.	1.4	1
1159	Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Advanced Drug Delivery Reviews, 2023, 197, 114822.	6.6	19
1166	Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation. , 2023, , 489-512.		0
1176	<sup>13</sup> C Isotope Labeling and Mass Spectrometric Isotope Enrichment Analysis in Acute Brain Slices. Methods in Molecular Biology, 2023, , 181-194.	0.4	0
1181	Factors Determining the Susceptibility of Fish to Effects of Human Pharmaceuticals. Environmental Science & Technology, 2023, 57, 8845-8862.	4.6	6
1182	Modeling the Blood-Brain Barrier Using Human-Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2023, , 135-151.	0.4	3

#	ARTICLE	IF	CITATIONS
1200	An Overview of Chemistry, Kinetics, Toxicity and Therapeutic Potential of Boldine in Neurological Disorders. <i>Neurochemical Research</i> , 0, , .	1.6	0
1206	Nanodiagnostics and targeted drug delivery: integrated technologies. , 2023, , 353-393.		1
1215	Microtubule stabilising peptides: New paradigm towards management of neuronal disorders. <i>RSC Medicinal Chemistry</i> , 0, , .	1.7	0
1220	Using Pre-Clinical Studies to Explore the Potential Clinical Uses of Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem cells. <i>Tissue Engineering and Regenerative Medicine</i> , 0, , .	1.6	1
1223	Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases. <i>Nanoscale Horizons</i> , 2023, 9, 14-43.	4.1	1
1245	Role of Stem Cells and Derived Exosomes as a Novel Therapeutic Agent against Alzheimerâ€™s and Parkinsonâ€™s Disease. , 2023, , 231-258.		0
1246	Targeting Specific Barriers. , 2023, , 219-262.		0
1260	A state-of-the-art liposome technology for glioblastoma treatment. <i>Nanoscale</i> , 2023, 15, 18108-18138.	2.8	0
1284	A 3D Microfluidic Device with Vertical Channels toward In Vitro Reconstruction of Blood-Brain Barrier. , 2023, , .		0
1290	Nanocarriers: Potential Vehicles for Managed Delivery of Bioactive Compounds in Therapeutics. , 2023, , 135-160.		0
1318	æŸ”æ€šçŸžç»æžŸé’:â½“â%çš,,â¼ç,1â€ç¼ç,1âšæœ³æŸéœœæ±. <i>Journal of Zhejiang University: Science B</i> , 2024, 25, 1536167.		0
1324	Challenges in Drug Development for Neurological Disorders. , 2023, , 27-45.		0
1325	Brain-Drug Delivery Through Intercellular Junction of Blood Brain Barrier (BBB) Using Cold Atmospheric Plasma. <i>Lecture Notes in Networks and Systems</i> , 2024, , 98-103.	0.5	0